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Abstract
Arginine methylation is a prevalent post-translational modification that is found on
many nuclear and cytoplasmic proteins, and has been implicated in the regulation of gene
expression. CARM1 is a member of the protein arginine methyltransferase (PRMT) family of
proteins, and is a key protein responsible for arginine methylation of a subset of proteins
involved in transcription. In this thesis I examine some of the mechanisms through which
CARM1 contributes to global transcriptional regulation.
Using a ChIP-DSL approach, we show that the p/CIP/CARM1 complex is recruited
to 204 proximal promoters following 17β-estradiol (E2) treatment in MCF-7 cells. Many of
the target genes have been previously implicated in signaling pathways related to
oncogenesis. JAK2, a member of the Jak/Stat signaling cascade, is one of the direct E2dependent targets of the p/CIP/CARM1 complex. Following E2-treatment, histone
modifications at the JAK2 promoter are reflective of a transcriptionally permissive gene, and
we observed modest increases in RNA and protein expression. Notably, E2-induced
expression of Jak2 was diminished when p/CIP or CARM1 were depleted, suggesting that
the p/CIP/CARM1 complex is required for the observed transcriptional response.
Collectively, these results suggest that E2-dependent recruitment of the p/CIP/CARM1
complex causes JAK2 to become ‘poised’ for transcription, a finding that may be extendable
to other target genes and signalling pathways. Furthermore, bioinformatic examination of
p/CIP/CARM1 target promoters suggests that transcription factor crosstalk is the favored
mechanism of E2-dependent p/CIP/CARM1 complex recruitment.
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Using ChIP-Seq, we identified genomic regions to which CARM1 is recruited.
Subsequent characterization of binding events suggest a role for CARM1 in transcriptional
elongation, and implicate the transcription factor PAX1 as a novel mechanism through which
CARM1 can be recruited to the genome. Identification of CARM1-dependent differentially
expressed genes revealed that direct recruitment of CARM1 is not essential for the majority
of its transcriptional effects in MEFs. However, CARM1 does play a critical role in cellular
growth and proliferation, and in the absence of CARM1, the expression of many cell cycle
regulators is dramatically affected.
Collectively, this work provides insight into some of the mechanisms through which
CARM1 modulates transcription, and highlights its importance in diverse cellular processes.

Keywords
Transcription, transcriptional regulation, chromatin, histone modifications, chromatin
immunoprecipitation (ChIP), cancer, estrogen, coregulators, steroid receptor coactivators,
arginine methylation, p/CIP, CARM1
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Chapter 1

1

General Introduction

1.1 Gene Expression
Gene expression is a general term applied to the process in which the genetic
information encoded within DNA becomes processed into a functionally useful form(s).
The first step in this process is transcription, wherein RNA Polymerase (RNAP) reads the
DNA template strand and produces a primary RNA transcript. The primary transcript is
then processed and/or spliced, giving rise to mature mRNA, in addition to the more
recently discovered non-coding RNA (ncRNA)

[1]. Transport of mRNA from the

nucleus to the cytoplasm is essential for protein production, termed translation, which
takes place in ribosomes. An overview of the levels at which gene expression can be
regulated is shown in Figure 1-1, and can conceptually be broken down into four
component

sections:

transcriptional

regulation,

post-transcriptional

regulation,

translational regulation, and post-translational regulation.
While each cell within an organism is encoded with the same genetic information,
there are vast differences in the size, shape, function, and lifespan of each cell type.
These differences can be largely accounted for by distinct cellular gene expression
profiles, with genes being expressed in a tissue/cell-specific and time-dependent manner.
Development in particular is characterized by major changes in gene expression
corresponding to changes in cell determination, and resulting in the differentiation of
cells into distinct lineages. Many cellular processes are common to all cell types, and so
all cells will express certain common genes and proteins. It has been determined that a
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given human cell expresses between 30-60% of approximately 25,000 genes at any given
time [1,2]. Notably, aberrant regulation of transcription is often involved in disease
states, including cancer.

1.2 Transcriptional Regulation
The work presented within this thesis is primarily concerned with the regulation
of gene expression at the level of transcription. A complex association between cis-acting
regulatory DNA sequences, trans-acting DNA-binding proteins, and chromatin
compaction modulates transcriptional regulation [3,4]. Regulatory DNA sequences, also
known as response elements, generally represent sites within the genome at which protein
binding can occur. These elements can occur both proximal to and/or distal from the gene
to be transcribed. Proximal regulatory sequences occur within the promoter region,
consisting of the core promoter and adjacent regulatory elements, while distal regulatory
sequences can exist up to 1Mbp from the transcription start site (TSS). Distal regulatory
elements can include enhancers, silencers, insulators, and locus control regions [4].
Trans-acting DNA-binding proteins bind to cis-acting regulatory sequences and function
to either activate or repress transcription.
Transcription classically consists of three stages: initiation, elongation, and termination
[1]. Each stage involves multiple factors and a specific sequence of events in order to
proceed, with an RNAP common to all stages. There are three different RNA
Polymerases in eukaryotes, each responsible for the transcription of a different form of
RNA. RNAPI synthesizes ribosomal RNA (rRNA); RNAPII is responsible for the

3

Figure 1-1 Regulation of gene expression
Overview of gene expression, highlighting the various points at which regulatory control is
exerted, as well as the some of the mechanisms in regulation. Figure reproduced from Banks et al.
2000 [5].
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production of messenger RNA (mRNA), as well as several types of noncoding RNAs;
and RNAPIII generates primarily transfer RNA (tRNA). RNAPII is responsible for the
production of transcripts from protein-coding genes, and its role in transcription has been
extensively characterized [6,7].
Prior to initiation, and the addition of the first nucleotide in the mRNA transcript,
there are many pre-initiation steps that ultimately make transcriptional initiation a critical
regulatory step in the conversion of DNA to RNA. The key factors required for
transcription initiation include RNAPII, general and specific transcription factors,
Mediator, as well as proteins that possess chromatin-modifying and chromatinremodeling activities. RNAPII is the enzyme that synthesizes mRNA from the DNA
template during transcription. Its recruitment is dependent on a variety of transcription
factors, and its activity and processivity can be affected by post-translational
modifications

[3,8]. General transcription factors help localize RNAPII to the core

promoter of the gene to be transcribed, and participate together with RNAPII as part of
the transcription initiation complex [3,4].
Specific transcription factors can be defined as sequence-specific DNA binding
proteins that become recruited to regulatory regions, such as the proximal promoter or
distal enhancer regions of specific populations of genes to be transcribed. Recruitment of
specific transcription factors often occurs in response to an extrinsic signal, or in a
developmentally-timed manner.

The specific TFs can interact with the general

transcriptional machinery described above, and drive activation or repression of
transcription [3]. Both general and specific transcription factors can also interact with

5

coregulatory proteins which often act as mediators of their interaction, and modulators of
transcription factor activity [3].
Initially, a pre-initiation complex forms on selected promoters upstream of the
TSS, involving binding of general transcription factors and RNAPII. Activators and/or
repressors that will control the rate of transcription can also participate as part of the preinitiation complex. Transcriptional initiation progresses through promoter melting,
clearance, and escape, until an RNAPII elongation complex is formed and the transcript
becomes extended [4]. The C-terminal domain of RNAPII is an important regulatory
component, consisting of multiple heptapeptide repeats, which can be extensively posttranslationally modified [9]. Phosphorylation of the C-terminal domain of RNAPII is
critical for activation, and immediately precedes the onset of transcriptional elongation
[3,10,11].
In vivo, the packaging of DNA complicates transcription further, as access to
promoter and enhancer regulatory elements can be limited by chromatin condensation.
Chromatin-modifying and chromatin-remodeling proteins are therefore critically
important during transcriptional initiation, to alter the packaging of DNA such that the
regions containing genes to be expressed, and their associated regulatory regions, are
accessible to the general transcriptional machinery. A more detailed examination of the
role that chromatin plays in transcriptional regulation is the focus of the following
section.
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1.3 Chromatin and Regulation of Transcription
In order to accommodate the nearly 2m of DNA within a cell’s nucleus, a
complex system of compaction is employed. Compaction of DNA is facilitated by a
group of proteins known as histones, and compacted DNA is referred to as chromatin, the
most basic subunit of which is a nucleosome. Nucleosomes are formed when
approximately 146bp of DNA is wrapped around an octamer of proteins made up of pairs
of the core histones (H2A, H2B, H3 and H4). A fifth histone is also involved in
packaging of chromatin; histone H1 acts as a stabilizer, interacting with linker DNA
between nucleosomes, and helping to facilitate further coiling into a 30nm fiber [12].
Subsequent looping and compression ultimately result in the final condensed
chromosome. An overview of this packaging is shown in Figure 1-2.
Packaging DNA in this manner adds a regulatory component by which gene
expression can be controlled. Chromatin can be classified as being in one of two states:
heterochromatin or euchromatin [1]. Heterochromatin is the term used to describe tightly
packed DNA, which is relatively inaccessible to transcriptional machinery, and is
therefore associated with gene silencing. In contrast, euchromatin constitutes more
loosely packed DNA, which is generally more gene rich, and accessible to regulatory
factors that can transcribe genes. Changes in DNA condensation, and by extension its
accessibility, can be a dynamic process, allowing for the expression of specific genes in a
temporally- or spatially-dependent manner.
Nucleosome structure adds a further complexity to gene regulation. When DNA is
wrapped around the core octamer, the structure allows for the protrusion of the amino
(N)-terminal tails of the core histones. These protruding tails are targets for a variety of
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Figure 1-2 DNA packaging - levels of chromatin compaction
DNA is sequentially packaged in cells, such that the double helix is coiled into
nucleosomes resembling “beads on a string”, and further packaged into higher order
structures, ultimately resulting in a fully condensed chromosome. Heterochromatin refers
to tightly packaged chromatin, repressive to transcription. Euchromatin refers to a more
open
chromatin
state,
more
conducive
to
gene
expression.
Credit: Darryl Leja/National Human Genome Research Institute
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Figure 1-3 Nucleosome Structure & post-translational modifications of histone tails
Top: Representative image of nucleosome structure; comprised of an octamer of histone proteins
around which DNA is wrapped. Evident are the N-terminal histone tails protruding outward from
the nucleosome. Bottom: Overview of known covalent histone tail modifications. Figure
reproduced from New York Academy of Science eBriefing 2011 and Xu 2013 [13].
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post-translational modifications that can affect gene expression, either by altering the
chromatin structure directly, or by bringing histone tails [and surrounding DNA] into
close proximity with regulatory factors thereby facilitating their functional interaction
(Figue 1-3).

1.3.1

The Language of Covalent Histone Modifications
Specific patterns of covalent histone modifications can be predictive of distinct

biological outcomes; in particular, specific combinations of modifications can serve as a
signal for transcriptional activation or repression. Allis and colleagues coined the phrase
‘the histone code’ to describe the observations that chromatin modifications could
cooperate with, or antagonize, one another to trigger different functional responses
[14,15]. Histone modifications such as acetylation, phosphorylation, methylation,
ubiquitination, and/or sumoylation, can alter transcriptional activity by changing the
compaction of the chromatin, thus altering the accessibility of transcriptional machinery
to DNA. Alternately, modifications can act as recognition elements for other factors that
will alter structure and/or regulate transcription

[16,17]. Broadly, three classes of

proteins can be associated with the histone code: ‘writers’, which deposit the
modification(s), ‘erasers’ remove the modification(s), and ‘readers’ or ‘effectors’ that
recognize the modified N-terminal residue(s) and mediate transcriptional consequences.
Acetylation is the best characterized among the histone post-translational
modifications, with a connection between histone acetylation and transcription first
documented in 1964 [18]. Generally, an increase in histone acetylation is predictive of
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transcriptional activation. Acetylation of histones occurs on lysine residues, and the
modification effectively neutralizes the positively charged residue, disrupting the ability
of the histone to interact with negatively charged DNA

[19-21]. Histone Acetyl

Transferases (HATs) are the enzymes responsible for acetylation of histones [22,23],
with Histone Deacetylases (HDACs) acting in the reverse capacity [24,25], to remove
the acetyl group(s) and allow the chromatin to return to a more transcriptionally
repressive heterochromatic state. Acetylated lysines can also act as an interaction surface
recognized by specific modules found within regulatory proteins such as bromodomains
[26,27], or tandem PHD (plant homeodomain) fingers [28,29]. Both of these domains
recognize acetylated lysines with hydrophobic binding pockets, and facilitate the
interaction by means of hydrogen bonding [29].
Histone phosphorylation occurs primarily on serine and threonine residues, and
has been associated with both transcriptional activation and repression. In addition,
phosphorylation has been implicated in DNA damage repair [30-32], and in chromosome
condensation during mitosis and meiosis

[33-35]. In a transcriptional context, the

addition of the negatively charged phosphate group to the positively charged histone tail
would be expected to cause decondensation of chromatin. Consistent with this
expectation, phosphorylation of histone H3 at serines 10 and 28, and at threonine 11 has
been associated with transcriptional activation, as well as with histone acetylation [3638]. Crosstalk with other modifications is a key component when interpreting histone
phosphorylation, with specific phosphate groups affecting the ability of nearby residues
to become acetylated [36-38] and/or methylated [39,40].
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Understanding the functional effects of methylation of lysine and arginine resides
within histones has proved to be a difficult endeavor. Multiple methyl groups can be
added to the same residue, complicating the interpretation of transcriptional
consequences; lysines can be mono-, di-, and tri-methylated, while arginines can be
mono-, and di-methylated (asymmetrically or symmetrically) [41,42]. Methylation of
lysine and arginine residues has been implicated in both activation and repression of
transcription [42]. Addition of methyl groups does not alter the charge of lysine or
arginine residues, and therefore does not drastically affect electrostatic interaction of the
positive histone tails with the negatively charged DNA. Instead, methylation of lysine or
arginine has been shown to provide interaction surfaces for effector proteins, which can
impact the chromatin compaction. Methylation of lysine groups is predominantly
achieved by a group of enzymes containing a SET domain [43], using S-adenosyl
methionine (SAM) as a methyl donor. The process is reversible, with two protein families
implicated in demethylating lysine residues: Lysine-Specific Demethylases (LSD) that
belong to the larger collection of amine oxidases [44], and the Jumonji-C (JmjC)domain-containing family of demethylases [45]. The number of protein domains found
to interact with methylated lysine continues to grow, and currently includes
chromodomains, PHD fingers, Tudor domains, WD-40 domains, and MBT domains
[17,46]. Some of these domains only recognize a specific histone lysine residue, and/or
residues that have been modified in a particular way, while others are more promiscuous
in their binding. For example, the Tudor domain of 53BP1 exclusively interacts with
dimethylated lysine 4 or 9 on histone H3 (H3K4me2, H3K9me2) and dimethylated lysine
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20 on histone H4 (H4K20me2), while the chromodomains of HP1 and CDY1 recognize
mono-, di-, and tri-methylated lysine 9 on histone H3 (H3K9) [46].
The Protein Arginine Methyltransferase (PRMT) family is responsible for histone
arginine methylation, and also uses SAM as a donor. In 2007, Chang et al. suggested that
Jumonji domain-containing protein 6 (JMJD6) could demethylate histone H3 at arginine
2 (H3R2) and histone H4 arginine 3 (H4R3)

[47]. However, this finding was not

reproducible, and it could be argued that a ‘true’ arginine demethylase has yet to be
identified. However, the modification is not irreversible; peptidylarginine deiminase
(PADI) enzymes can convert methylated [and unmethylated] arginine residues to
citrulline [48,49]. Readers of methylated arginine residues have also been discovered,
with the PHD motif-containing ADD domain of DNMT3A shown to interact with a
symmetrically dimethylated arginine residue on histone H4 (H4R3me2s)

[50]. In

addition, Tudor domains have been found to recognize asymmetrically dimethylated
arginines. For example, Tudor domain-containing protein 3 (TDRD3) [51] has been
shown to interact with the arginine methylated C-terminal domain of RNAPII, and this
association is important for transcriptional activation by the estrogen receptor (ER) at
some genes. Understanding of the dynamic regulation of histone lysine and arginine
methylation and demethylation, the factors involved in the deposition and removal of the
methyl groups, and the transcriptional and functional roles of these modifications,
continues to develop.
Finally, ubiquitination or sumoylation can also occur on lysine residues.
Ubiquitination of histones generally allows chromatin decondensation, access for
transcriptional enzymes, and increased transcription [52]. Ubiquitination of histones
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primarily occurs on histone H2A and H2B. Histone H2A ubiquitination has been
implicated in transcriptional repression [53], while modification of histone H2B has been
associated with activation and has been shown to promote other activating histone
modifications in both yeast and mammalian systems

[54-57]. Addition of small

ubiquitin-related modifier (SUMO) groups to histones and transcription factors is related
to gene silencing, as deposition of this modification has been shown to recruit
transcriptional repressors [58,59].
Interpretation of the vast combinations of covalent histone modifications is an
ongoing and highly active area of research, with the application of high throughput,
genome-wide technologies such as ChIP-Seq greatly increasing our ability to identify
patterns of histone modifications. The existence of multiple recognition motifs for
individual marks, as in the case of lysine methylation in particular, attests to the
complexity of the ‘code’. Furthermore, the binding affinity of a reader for a specific
modification can be enhanced or inhibited by adjacent marks, with many chromatin
regulatory proteins containing more than one ‘reader’ domain [17]. Ultimately, while
any single histone tail modification can suggest a particular chromatin state and
transcriptional consequence, it is the combinatorial makeup of the modifications as a
whole, and the cross-talk between them that ultimately regulated gene expression.

1.4 Transcription Factors
Transcription factor is a general term for any protein directly involved in
regulating transcriptional initiation. These regulatory proteins typically recognize and
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interact with DNA in a sequence-specific manner. DNA-protein interaction can be
attributed to several known DNA-binding structural motifs. Transcription factors can be
grouped based on the motif(s) they contain, the most common of which include helixturn-helix, zinc finger, leucine zipper, and helix-loop-helix.
The first DNA binding domain to be identified was the helix-turn-helix [60]. This
motif consists of two α helices connected by a short chain of amino acids that comprise
the turn. The two helices are held at a fixed angle, allowing for the interaction of the Cterminal helix with the major groove of the DNA [1,61,62]. This interaction is sequence
specific, and the variability in amino acid sequence both within the helix-turn-helix
region, and in the overall protein allow for variability in binding specificity. Helix-turnhelix-containing transcription factors bind as symmetric dimers to symmetrically
arranged half-sites within the DNA sequence [1,63].
DNA-binding motifs that include zinc ions as structural components are known as
zinc fingers. A combination of cysteine and histidine residues within the amino acid
sequence is used to coordinate the zinc ion(s). Zinc finger-containing proteins are
numerous and are generally grouped based on their structure, with the first type of zinc
finger protein discovered containing an α helix and two-stranded β sheet held together by
zinc, coordinated by two cysteine and two histidine residues [1,62,64]. This type of zinc
finger can occur in clusters, with repeating patterns of α helices/ β sheets evident. The α
helix of each finger interacts with the major groove of the DNA, and the repeating pattern
of zinc finger elements ensures a strong DNA-protein interaction [62]. The number of
repeating ‘fingers’ can determine the specificity of this type of zinc finger-containing
protein [1]. Another example of a zinc finger DNA binding domain involves two α
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helices held together by two cysteine-coordinated zinc atoms, similar in structure to the
helix-turn-helix motif previously described. Like helix-turn-helix containing proteins, this
type of zinc finger protein typically functions as a dimer, with one of the α helices
interacting with the major groove. Notably, this type of zinc finger domain is found
within the DNA binding domains of nuclear hormone receptors [1,62]. Many other
structural subclasses of zinc fingers exist [64], but their properties are beyond the scope
of this thesis.
Leucine zippers constitute a third class of DNA binding domain. The leucine
zipper motif is made up of an α helix, with adjacent regions for dimerization and DNA
interaction [62]. Dimerization is facilitated by hydrophobic, luecine-rich regions within
each monomer, which come together to form a coiled-coil. Beyond the dimerization
region, the helices of each monomer are separated, with the resulting structure resembles
a Y-shape, and allowing for interaction with the major groove of DNA

[1,65].

Heterodimerization of DNA binding proteins, such as leucine zippers, can also occur,
thereby expanding the number of possible DNA-binding specificities.
Related to the leucine zipper is the helix-turn-helix motif, which consists of a
short α helix connected by a loop to a second, longer, α helix. The loop is quite flexible,
allowing the helix-loop-helix protein to fold on itself, thereby facilitating both
dimerization and DNA interaction [1,65]. Helix-loop-helix proteins can also form either
homo- or hetero-dimers.
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1.4.1

Nuclear Receptors
Nuclear receptors (NRs) are a class of proteins that are responsible for sensing

and responding to the presence of a variety of hydrophobic ligands, including steroids,
retinoic acid, thyroid hormones, and vitamin A and D derivatives [3]. Groups who used
tritiated estradiol to isolate and characterize constituents that bind estrogen in the rat
uterus [66,67] first suggested the existence of protein receptors for steroid hormones in
the 1960s. Advancing technology, specifically recombinant DNA technology in the 70s
and 80s allowed for specific receptors to be cloned and sequenced. In 1985, the
glucocorticoid receptor became the first nuclear hormone receptor cloned [68], with
estrogen receptor alpha (ERα) identified shortly thereafter [69]. The NR superfamily
now consists of 48 known members in humans, and has documented roles in processes
such as metabolism, differentiation, and development [74].
Collectively, the NR transcription factors share a common domain architecture,
consisting of six regions [3,70-72]. The most amino (N)-terminal domains contain the
ligand (hormone)-independent activation function 1 (AF-1). This region allows for some
transcriptional activity from the NR in the absence of ligand. Next, is the DNA-binding
domain (DBD); a region characterized by a pair of zinc fingers, which bind to specific
palindromic recognition elements within the DNA, termed hormone response elements
(HREs). A hinge region provides flexibility and has been found to play a role in nuclear
localization, DNA binding, and coactivator recruitment. The ligand-binding domain
(LBD) contains the ligand-dependent activation function 2 (AF-2) and consists of 12 αhelices arranged in three layers, forming an antiparallel “α-helix sandwich”. This region
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contains interaction surfaces for coactivator and corepressor proteins. Lastly, the carboxy
(C)-terminal domain, which is highly variable, facilitates receptor dimerization.
The NR superfamily can be categorized into several subgroups, including steroid
hormone receptors, retinoid X receptor (RXR) heterodimers, as well as two classes of
orphan receptors [for which there are no known ligands], which function as either
heterodimers with other NRs, or as monomeric receptors, binding HRE half-sites
[70,73]. Steroid receptors typically reside in the cytoplasm, and translocate to the nucleus
upon ligand binding; whereas, RXR heterodimers are usually retained in the nucleus
regardless of ligand binding status [74].
In the canonical mechanism of NR action, the ligand binds its cognate receptor in
the cytoplasm or nucleus of the cell, depending on the receptor type, causing a change in
receptor conformation that facilitates dimerization. Ligand-bound receptors then
translocate to the nucleus if necessary and interact via the zinc fingers of the DBD with
specific DNA sequences known as hormone response elements (HREs). HREs were
originally thought to be found within the 5’ proximal regulatory region of genes, but are
now known to also be found at distal enhancers [71,75]. A pair of palindromic six
nucleotide sequences separated by three nucleotides makes up the typical HRE, for
example ERα recognizes the sequence AGGTCAnnnTGACCT [76]. Once bound to the
HRE, subsequent recruitment of coactivators leads to the decondensation of chromatin
through active remodeling and histone modification. Receptor-coactivator complexes
recruit general transcription factors and RNAPII, and maintain an open chromatin
conformation to allow for transcription initiation and elongation. It is important to note
that NR recruitment can also lead to transcriptional repression; both by actively
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repressing expression in the absence of ligand through interaction with corepressor
proteins [71,77], and/or by antagonistically inhibiting the activity of other transcription
factors [71,78].
The classical view of NR action, based primarily on biochemical studies at
selected genes, does not provide a complete understanding of their functionality.
Evolving technology, specifically chromatin immunoprecipitation coupled to genomic
microarray (ChIP-chip) or high throughput sequencing (ChIP-Seq), has allowed for the
evaluation of NR recruitment genome wide. The first NR to be mapped in this manner
was ERα. Surprisingly, this analysis revealed a predominance of ERα binding occurring
at regions far distal from the TSS of genes [79]. Subsequent studies have confirmed that
the majority of ERα binding occurs more than 10 kb from the nearest TSS [80,81]; an
observation that has been extended to other NRs, including glucocorticoid receptor (GR),
peroxisome proliferator-activated receptor gamma (PPARγ), and vitamin D receptor
(VDR) [82-84]. The requirement for sequence specific binding motifs (HREs) has also
been called into question as NRs have been found to interact with regions that do not
contain HREs [79,81], and analysis of NR cistromes has shown that NRs can bind at
sites containing HRE half-sites as well as other noncanonical recognition sequences [85].

1.4.2

The Estrogen Receptor
Estrogens are a family of steroid hormones, which are involved in regulating

numerous processes ranging from development, to sexual maturation and behavior. On a
cellular level, estrogens, most notably E2, are essential mediators of regulatory pathways
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responsible for the normal proliferation and differentiation of cells [86,87]. E2 has been
epidemiologically and clinically linked to breast cancer incidence, and unsurprisingly, the
deregulation of its downstream signaling cascades is a common feature of carcinogenesis
[88].
The cellular effects of E2 are mediated through the estrogen receptor (ERα),
which is primarily expressed in breast, uterus, ovary, testes, epididymis, bones, and brain
[72]. In the classical mechanism of estrogen signalling, as in the canonical NR response
previously described, ligand (E2) binding triggers receptor dimerization and interaction
with estrogen response elements (EREs), specific palindromic DNA sequences within the
regulatory regions of target genes [76,89-91]. ER activation can also promote gene
expression in the absence of direct DNA binding, through interactions with other DNAbound transcription factors such as activator protein-1 (AP-1) and specificity protein-1
(Sp1) [92-94]. Additionally, a Forkhead binding motif has been found to be enriched
adjacent to a percentage of ER binding sites [79], suggesting that the DNA-bound ER
cooperates with Forkhead transcription factors on many targets.
ERα activity is regulated at many levels [72]; the most relevant of which for the
purposes of this thesis is through its E2-dependent interaction with coregulator proteins.
Importantly, E2 binding to the ER induces a conformational change that repositions the
C-terminus and creates an adaptor surface that facilitates the recruitment of coregulator
proteins. Coregulators [both coactivators and corepressors] that bind the ER can alter the
chromatin architecture directly [95], function as adaptors/bridging factors which recruit
additional coregulator proteins to target genes

[96,97], or interact directly with

components of the core transcriptional machinery [98,99].
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1.5 Transcriptional Coregulators
Transcriptional coregulators are protein factors that can interact with transcription
factors and modulate their activity. Many of these proteins contain a variety of enzymatic
activities and can exert functional control over transcription [100,101]. In addition,
coregulators can act as bridging proteins, interacting with transcription factors and
allowing for the assembly of large, multicomponent enzymatic complexes

[102].

Coregulators generally fall either into the categories of coactivators, which enhance gene
expression, or corepressors, which are suppressive. Coactivators can be further classified
as primary coactivators, which come into direct contact with the transcription factors, and
secondary coactivators, which participate in the coregulator complexes but do not directly
bind TFs [102,103]. To date, almost 350 coregulators have been identified based on
these criteria (www.NURSA.org). Collectively, these proteins play a critical role in
cellular processes, and provide a level of diverse, dynamic, and adjustably-responsive
control specifically for transcription.

1.5.1

Steroid Receptor Coactivators
As discussed in section 1.4.1, NRs are ligand-dependent transcription factors that

regulate gene expression and affect various physiological functions. It was initially
believed that NRs alone allowed RNAPII and general transcription factors to assemble at
promoters and control transcription. However, when it was shown that overexpression of
one NR could indirectly inhibit the activity of another, and that in vitro assays involving
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only NRs and general transcriptional machinery produced at best modest transcriptional
responses, it was suggested that NRs may share a common set of coregulatory effector
proteins required for full transcriptional response. [104-106]
The first such coregulatory protein, steroid receptor coactivator 1 (SRC1/
NCOA1), was identified by Onate et al. in 1995 [107]. SRC1 was found to interact with
NRs in a ligand-dependent manner, robustly activating transcription. Two other
homologous proteins were cloned soon after, completing the p160 SRC family: SRC2
(also known as NCOA2, TIF2, GRIP1) [108,109], and SRC3 (also known as p/CIP,
RAC3, AIB1, ACTR, TRAM1, NCOA3) [110-114].
The steroid receptor coactivator (SRC) proteins are each approximately 160kDa
in size, share 50-55% sequence similarity [115], and have three conserved structural
domains (Figure 1-4). The N-terminus contains a basic helix-loop-helix-Per/ARNT/Sim
(bHLH-PAS) domain. This region is the most highly conserved among family members
and is required for protein-protein interactions important for transcriptional activation,
including direct interaction with transcription factors such as myogenin and myocytespecific enhancer factor 2C (MEF2C), and with enhancer proteins [116,117]. Evidence
also suggests that in the case of some family members, this domain can be implicated in
nuclear localization [118,119] and in proteasome-dependent turnover [119]. The central
nuclear receptor interaction domain (NRID) contains three LXXLL motifs that form
amphipathic α-helices, and are responsible for direct contact with NRs. Sequences
adjacent to this domain contribute to the specificity of NR binding [120]. Finally, the Cterminus contains two activation domains (AD1 and AD2), which allow for SRCs to
interact with secondary coregulators. AD1 interacts with CBP (CREB-binding protein)
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and the histone acetyltransferase (HAT) p300. AD2 interacts with the arginine
methyltransferases coactivator-associated arginine methyltransferase 1 (CARM1) and
protein arginine methyltransferase 1 (PRMT1). The C-terminal region of SRC1 and
p/CIP contain minimal intrinsic HAT activity. However, specific substrates have not been
well characterized, and this activity is of much lesser importance than the bridging role of
SRCs in assembling complexes of transcriptionally active components.
The series of events involved in NR- and coactivator-mediated transcriptional
activation has been extensively characterized. In 2003, Métivier et al. used a
comprehensive chromatin immunoprecipitation (ChIP)-based approach to provide
evidence of the ordered, cyclical, and combinatorial recruitment of cofactors in response
to E2 in MCF-7 cells [97]. This study demonstrated that at least 30 different proteins
become engaged on the pS2 promoter in the presence of E2, and elucidated the kinetics
of cofactor recruitment over time; revealing three cycles of protein interaction. SRC1 or
p/CIP was found to associate with pS2 in the two transcriptionally productive cycles post
E2 treatment [97]. Specifically, SRC1 and/or p/CIP were found to cycle on an off the
promoter every 50 min after E2 treatment, initially found to interact 45 min after
treatment [97]. Recruitment of these SRC proteins corresponds with the presence of
ERα, and in fact, involves their interaction with ERα [97]. There are limitations with this
study, including the fact that it focuses only on a single E2-responsive promoter, and that
cycling rate in a population of cells is not necessarily reflective of physiological
conditions. Nevertheless, it is clear that NR signaling in response to E2 is dynamic and
includes a level of specificity and redundancy among coregulators, which ultimately
work together to achieve the required transctiptional outcome. Once bound to the NR,
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Figure 1-4 SRC structural domains and interacting proteins
SRC proteins consist of three structural domains. The N-terminal basic helix-loop-helixPer/ARNT/Sim (bHLH-PAS) domain, the central nuclear receptor interaction domain
(NRID), and the C-terminal domain, which consists of two activation domains (AD1 and
AD2). SRCs coactivate nuclear receptors (NRs), as well as numerous transcription factors,
and coordinate the recruitment of a variety of secondary coregulatory proteins. This is a
representation of some of the SRC-interacting proteins, mapped to the region with which
they make contact. Figure is reproduced from Johnson et al 2011 [121].
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SRC family members act as scaffolding proteins and recruit many secondary
coregulators, including the acetyltransferase p300 and methyltransferase CARM1
[122,123]. CBP/p300 and CARM1 can then both modify the histones, promoting
transcriptional activation (Figure 1-5) [124].
SRC functional effects are ubiquitous, primarily due to the ability of the family
members to interact with and modulate the activities of a wide range of transcription
factors, in addition to NRs (Figure 1-4), such as NFκB [125], SMADs [126], E2F1
[127], STATs [128], RB [129], and p53 [130]. Extending the number of cellular
process that are impacted by SRCs, interactions have also been shown with a variety of
oncogenes, tumor suppressors, kinases and phosphatases, ubiquitin and SUMO (small
ubiquitin-related modifier) ligases, as well as with other coregulators.

1.5.2

Post-translational Modifications of SRCs
Numerous studies have demonstrated that SRCs undergo post-translational

modifications (PTMs) in response to numerous stimuli. These PTMs include
phosphorylation, ubiquitination, sumoylation, acetylation, and methylation. These
modifications can affect protein stability, interaction with TFs and secondary
coregulators, in addition to transcriptional activity of SRCs (Figure 1-6).
Phosphorylation of SRCs can change their affinity for specific NRs and/or affect
NR-dependent gene expression. SRC1 can be phosphorylated at Thr1179 and/or Ser1185
in response to epidermal growth factor (EGF) or interleukin 6 (IL-6). This results in
enhanced association with p300 and CBP and increases NR-dependent
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Figure 1-5 SRC-mediated coactivation of NRs
SRC proteins are recruited to liganded NRs, interacting through their LXXLL motifs in the
central nuclear receptor interacting domain (NRID). Secondary coregulatory proteins and
chromatin remodeling complexes such as SWI/SNF are then recruited through their- basic helixloop-helix-Per/ARNT/Sim (bHLH-PAS) or C-terminal AD1 and AD2 domains, respectively. As
shown, p300/CBP interacts with SRCs via the AD1 domain, while CARM1 contacts AD2. These
secondary coactivators modify the chromatin and bridge the NR complex with the general
transcription machinery to elicit transcriptional activation. Figure reproduced from Johnson et al
2011 [121].
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Figure 1-6 Functional consequences of SRC post-translational modifications
In response to a variety of signals SRC proteins can be post-translationally modified, thereby
affecting intracellular concentration, activity, and specificity. Documented modifications include
phosphorylation, ubiquitination, sumoylation, acetyaltion, and methylation. Figure reproduced
from Xu et al 2009 [141].
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transcription,

[131,132]. p/CIP (SRC3) contains nine sites (Thr24, Ser101, Ser 102,

Ser505, Ser543, Ser857, Ser860, Ser867, Tyr1357) that can be phosphorylated by a
variety of different kinases, including but not limited to MAPK, IKK, and AKT [133136]. The ability to accept signals from multiple pathways, and the number of different
kinases that can contribute to regulation p/CIP highlight the central nature of p/CIP, and
other SRCs as integrators of many different signalling pathways. As an example of the
functional consequences of p/CIP, phosphorylation of Tyr1357 increases its binding to
p300 and transcription factors, thereby promoting ERα-, PR-, and NFκB-dependent
transcription [136]. In addition, p/CIP phosphorylation can lead to its redistribution to
either the nucleus or to the cytoplasm, altering its availability to regulate different
transcriptional effects [118,137,138].
Two sites of ubiquitination have been identified within the NRID of p/CIP [139].
Polyubiquitination at these sites occurs following phosphorylation events, linking
transcriptional activation with p/CIP degradation and transcriptional turnover
[139,140]. Sumoylation, in contrast, can protect SRCs against degradation, by targeting
common lysine residues and preventing ubiquitination. Sumoylation can also cause
SRCs to adopt a transcriptionally inert conformation [141,142].
Acetylation and methylation of SRCs can also occur, affecting their affinity for
interacting proteins. For example, p/CIP can be acetylated by p300 and CBP, which
results in disassembly of the coactivator complex and terminates transcription [123].
Methylation of p/CIP by CARM1 also causes complex dissociation [143,144], and
leads to p/CIP degradation [144].
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Collectively, post-translational modification(s) of SRC proteins occur as the result
of many different signalling pathways, and combine to fine-tune the coactivator
potency, cellular concentration, and selectivity of the SRCs, ultimately allowing for
precise regulation of gene expression programs [145].

1.5.3

p/CIP
p/CIP (p300/CBP interacting protein) was originally identified in a region of

chromosome 20 (20q13) that is frequently amplified in breast cancer, and was
consequently named amplified in breast cancer-1 (AIB1) [110]. This member of the
p160 family of steroid receptor coactivators was independently cloned by several other
groups and assigned a different name by each: steroid receptor coactivator-3 (SRC3)
[146], activator of thyroid hormone and retinoid receptor (ACTR)

[111], receptor

associated co-activator-3 (RAC-3) [112], thyroid hormone receptor activating molecule
(TRAM) [113], and p300/CBP interacting protein (p/CIP) [114]. p/CIP is generally the
name given to the mouse homolog of SRC3, however we use this name interchangeably
when referring to either the mouse or human protein. These assigned names are quite
revealing of function, as p/CIP has been shown to interact with and enhance the activity
of several nuclear receptors, including ERα, retinoic acid receptor (RAR), PR, and
thyroid hormone receptor (TR) [95,112-114]. In addition, p/CIP interacts with a variety
of coregulator proteins, including CBP and CARM1 [123,146].
p/CIP expression is detectable in a multitude of tissue types, including muscle,
heart, lung, placenta, pancreas, kidney, brain, liver, uterus, pituitary, testis, and mammary
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gland [111,113,126,146,147]. Mouse models in which p/CIP is knocked out exhibit
growth retardation and a reduced adult body size, which appears to be in part due to
reduced IGF-1 levels [147,148]. While male reproductive function is slightly reduced,
there are significant defects in female reproduction. In p/CIP null female mice, sexual
maturation is delayed, mammary gland ductal growth is reduced, and reproductive
potential is diminished [147]. Estrogen levels were lower in p/CIP knockout mice when
compared to age-matched wild type littermates, corresponding to the observed
reproductive phenotype [147].
Additive severity of SRC knockouts was observed when double-knockout mouse
models were generated, suggesting that there exist cooperative functions among family
members. When SRC1 and p/CIP are simultaneously knocked out, most mice die before
birth [149]. Those who survive exhibit defects in metabolism; specifically, compromised
regulation of genes involved in adipogenesis and mitochondrial uncoupling. Leptin levels
are increased in these mice, and a defect in adaptive thermogenesis coupled with
developmental arrest in intercapsular brown fat means they are resistant to obesity due to
a high basal metabolic rate.

1.5.4

p/CIP in Breast Cancer
Each of the SRC family members has been found to be overexpressed in human

cancers [145], with roles in promoting cancer initiation, progression, and metastasis
through a variety of pathways. p/CIP is the most frequently amplified SRC in cancer,
with a notable association in hormone-promoted breast and prostate cancers [145]. While
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in normal breast tissue, p/CIP levels are typically low, in breast cancer, p/CIP mRNA is
overexpressed in 13-64% [110,150-152] of different tumor cohorts, and p/CIP protein is
overproduced in 10-25% [153-155]. Overexpression of p/CIP correlates with increased
tumor size and grade, tamoxifen resistance, and poor disease-free survival
[110,150,154,155].
Several mouse models have been used to elucidate the exact role(s) of p/CIP in
breast cancer initiation and progression. MMTV-driven overexpression of p/CIP in the
mouse resulted in the formation of spontaneous mammary tumors, thereby solidifying the
role of p/CIP as an oncogene [156]. However, tumors were also observed in the uterus
and pituitary in this model, the result of nonspecific MMTV-dependent expression. In
addition, corresponding to observations from p/CIP knockout mouse models, p/CIPoverexpressing mice have altered [hyperactive] IGF-1 signalling

[156]. In another

model, p/CIP null mice harbouring the MMTV-v-ras transgene breast tumour incidence
was decreased [157]. This mouse model also displayed altered IGF-1 signaling; lack of
p/CIP resulted in partial resistance to IGF-1, partly causing the suppression of mammary
tumorigenesis. In the HER2/neu-induced mammary tumorigenesis model, p/CIP
knockout also offered some protection from tumor development; with tumor formation
delayed in HER2+/+;p/CIP +/- mice and completely suppressed in HER2+/+;p/CIP-/- mice
[158]. Furthermore, compared with MMTV-HER2 control mice, MMTV-HER2 mice
heterozygous for p/CIP showed decreased phosphorylation of HER2, cyclinD1, and
cyclin E, and reduced activity of AKT, JUN N-terminal kinase and had a reduced rate of
proliferation [158]. Genetic ablation of p/CIP in MMTV-PyMT mice protected against
lung metastasis, as compared to WT/PyMT mice [159]. The role of p/CIP in breast cancer
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metastasis is attributed to its regulation of matrix metalloproteinases MMP2 and MMP9,
and their ability to mediate epithelial-mesenchymal transition (EMT) and cellular
invasiveness in this model system [159].
ER status can be used as an indicator to assess prognosis and determine treatment
strategies in breast cancer [160]. Since p/CIP acts as a coregulator for ERα, a great deal
of research has focused on the ability of p/CIP to mediate ERα-dependent gene
expression in the context of breast cancer. In the MCF-7 breast cancer cell line, p/CIP
depletion results in reduced recruitment of ERα to its target gene promoters,
corresponding with loss of transcription of these genes [161]. Furthermore, the absence
of p/CIP corresponds to decreased E2-mediated proliferation, survival, and soft-agar
colony formation [123]. Despite these observations, the literature remains quite conflicted
as to the significance of p/CIP in ER-dependent oncogenesis due to contradicting clinical
data correlating p/CIP expression with ER status [150,162].
In addition to its involvement in E2-responsive breast cencer, the role of p/CIP in
hormone-independent breast cancer has also been characterized. ER-negative breast
cancers are more aggressive and unresponsive to anti-estrogens [163]. p/CIP promotes
cellular growth of ER-negative cell lines, by coactivating E2F1-dependent transcription
of genes including E2F1, cyclin E, and cyclin-dependent kinase 2 (CDK-2) [127].
Growth and survival of breast cancer cells can also be modulated by p/CIP through its
interaction with AP-1 [164], and its coactivating role in NFkB-dependent transcription
has been linked with the expression of inflammation, immune response, and cell survival
[165]. In addition there is evidence of a link between p/CIP overexpression and activation
of the insulin-like growth factor (IGF)/PI3K/Akt signalling [156,157]. This pathway is
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related to cell growth, survival, and migration and is often found constitutively activated
in cancer [166].
There is extensive evidence linking p/CIP with breast cancer, and as discussed it
participates in the regulation of a wide variety of pathways and processes important for
oncogenesis. p/CIP expression is generally an indicator of poor prognosis, and can affect
responsiveness to treatments(s)

[145,155].

Continued characterization of p/CIP-

regulated genes will provide greater insight into the molecular mechanisms it uses to
promote cancer.

1.6 Protein Arginine Methylation
Arginine methylation is a post-translational modification found on both nuclear
and cytoplasmic proteins, which has been implicated in many different cellular processes,
including, but not limited to, transcriptional regulation, signal transduction, RNA
processing, and DNA repair. Defects in arginine methylation are known to be involved in
several disease processes, including cardiovascular disease, spinal muscular atrophy, and
cancer [167,168].
Early reports assert that approximately 2% of arginine residues in rat liver nuclei
are methylated, suggesting that this is a commonly occurring post-translational
modification [169]. Arginine methylation involves the covalent addition of one or more
methyl groups to the guanidino nitrogen of an arginine residue, adding bulkiness but not
affecting charge. There exist three known forms of methylated arginine: monomethylated
arginine (MMA), asymmetrically dimethylated arginine (ADMA), and symmetrically
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dimethylated arginine (SDMA) [170]. The generation of these modifications can be
attributed to a family of proteins collectively known as Protein Arginine
Methyltransferases (PRMTs).

1.6.1

The Protein Arginine Methyltransferase Family

To date, there have been 11 members of the protein arginine methyltransferase (PRMT)
family identified [171]. This protein family shares four conserved motifs that constitute
the catalytic methyltransferase domain, with additional domains conferring substrate
specificity (Figure 1-7). Members of the PRMT family can be subcategorized based on
their structure, or more commonly, on their specific methyltransferase activity. Using Sadenosyl-L-methionine as a donor molecule, Type I methyltransferases form ADMA,
while Type II form SDMA, on the guanidino nitrogen(s) of arginine residues, both
through a monomethylated intermediate (Figure 1-8) [172]. A third type of PRMT (Type
III) has more recently been suggested to only generate MMA. Type I is the most common
class of methyltransferases, and includes PRMT1, PRMT2, PRMT3, PRMT4 (CARM1),
PRMT6, and PRMT8. In comparison, only two family members are consistently
categorized as Type II (PRMT5 and PRMT9). PRMT7 has been shown to act either as
Type II or Type III, in a substrate-dependent manner. The final two members of the
family (PRMT10 and PRMT11) have yet to be enzymatically classified [171].
Most PRMTs methylate glycine- and arginine-rich patches (GAR motifs) within
their substrates [173], although specific recognition sites for each of the family members
are not well characterized. PRMT4, more commonly known as CARM1, is unusual

34

Figure 1-7 The Protein Arginine Methyltransferase Family
Schematic representation of the 11 members of the protein arginine methyltransferase (PRMT)
family. Each member of the family contain at least one conserved methyltransferase domain with
signature motifs I, post-I, II, and III and a THW loop. Unique domains are thought to contribute
to substrate specificity, and are shown in yellow. CARM1 is identified herein as PRMT4. Figure
reproduced from Esse 2012 [167].
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Figure 1-8 Types of methylation on arginine residues
Type I, II, and III PRMTs generate monomethylated arginine (MMA) on one of the guanidino
nitrogen atoms. Subsequent generation of asymmetrically dimethylated arginine (ADMA) is
catalyzed by Type I PRMTs (PRMT1, PRMT2, PRMT3, PRMT4/CARM1, PRMT6, PRMT8),
while Type II PRMTs (PRMT5, PRMT9) produce symmetrically dimethylated arginine residues
(SDMA). PRMT7 can act as either a Type II or III PRMT, and PRMTs 10 and 11 have not yet
been enzymatically classified. Figure reproduced from Yang et al 2013 [166].

36

among PRMTs since its substrates do not contain this GAR motif. CARM1 has been
found instead to methylate proline-, glycine-, methionine-rich (PGM) regions [174].
PRMTs are ubiquitously expressed, and affect a variety of important cellular
processes, including RNA processing, DNA repair, signal transduction, and
transcriptional regulation [170,171]. Of particular interest for the purposes of this thesis
is the role of PRMTs in transcription. Protein arginine methylation was initially detected
on histones [169], and occurs on the N-terminal tails of histone H3, H4, and H2A
[2,171,175]. Notably, there are several arginine residues within histone H3 that become
methylated (H3R2, H3R8, H3R17 and H3R26) [42,171]. Asymmetric dimethylation of
histone H3 generally correlates with activation of transcription [171,176].
Methylation of arginine residues also affects a wide array of non-histone
transcriptional regulatory proteins, including transcription factors, coregulators,
elongation factors, and RNAPII. Participation of PRMTs as components of coregulatory
complexes are well known to modulate the activity of NRs [98,177], as well as other TFs
[178]. In addition, arginine methylation of coregulatory proteins such as p/CIP and CBP
can affect their ability to form complexes, and their stability [143,144]. The PRMT
family members PRMT1 and PRMT5 have been shown to methylate the transcriptional
elongation factor SPT5 in its RNAPII-binding domain, resulting in transcriptional
pausing, wherein the engaged RNAPII accumulates just downstream of the promoter
region [179]. Furthermore, several components of the transcriptional elongationassociated Paf1c complex has been shown to interact with H3R17me2, thereby linking an
additional PRMT, CARM1, with elongation [180]. Finally, the C-terminal domain of
RNAPII can be methylated by CARM1, and contributes to transcriptional activation, in
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part by creating a docking site for the arginine methylation effector proteins such as
TDRD3 [181].

1.6.2

CARM1
Coactivator Arginine Methyltransferase 1 (CARM1), also known as PRMT4, is a

Type I PRMT originally identified based on its ability to interact with GRIP-1 (SRC-2), a
member of the p160 family of nuclear receptor coactivators [123]. CARM1 has since
been shown to interact with the two other members of the p160 family, SRC1 and SRC3
(more commonly referred to in this thesis as p/CIP). CARM1 was the first of the PRMTs
to be shown to regulate transcription [123]. Its role as a secondary coregulator of
transcription, synergistically enhancing gene expression of steroid-hormone-regulated
genes has been extensively studied [117].
CARM1 methylates substrates that can be broadly classified as possessing RNAbinding properties (PABP1, HuR, HuD, and splicing factors) [182-184], and substrates
that are involved in transcriptional regulation, including several residues of histone H3
(H3R17, H3R26) [185], p/CIP [143,144], and CBP/p300 [186,187]. Notably, the
methyltransferase activity of CARM1 is essential for its transcriptional effects [177].
CARM1 deletion in the mouse model revealed embryos that were small in size,
and die late in development or shortly after birth [188]. An elevated rate of lethality was
also noted for heterozygotes between birth and weaning. CARM1 knockout mice were
found to have insufficient lung development, blocked T-cell development in the thymus,
and altered lipid metabolism. CARM1 null mouse embryonic fibroblasts (MEFs), isolated
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from E12.5 embryos, do not support the methylation of CARM1 substrates, including
histone H3, p300 and PABP1. Furthermore, CARM1-/- MEFs were found to be defective
in E2-dependent signalling and in NFkB signalling pathways [188].

1.6.3

CARM1 in Cancer
CARM1 is overexpressed in breast, prostate, and colorectal cancer [189-191].

Recently, several large-scale clinical studies have confirmed that CARM1 levels are
elevated in aggressive breast tumors [192,193]. Furthermore, the expression of CARM1
in breast cancer is a predictor of diminished survival, and of poor disease-free survival
[192,193]. Notably, CARM1 expression plays a significant role in ERα-induced
proliferation and differentiation of the MCF-7 breast cancer cell line [194]. In fact, ERαregulated gene expression has been shown to rely on the presence of both p/CIP and
CARM1

[195]. Since, p/CIP itself has minimal intrinsic enzymatic activity, and

primarily acts to recruit additional coregulators, it follows that CARM1 is likely an
important mediator of the oncogenic effects attributed to these ERα-dependent genes.
CARM1-dependent methylation has been implicated in many additional pathways
and processes commonly deregulated in cancer

[170], including the DNA damage

response [196], regulation of the cell cycle [195], and WNT signalling [197]. In
addition, CARM1 is involved in promoting a favorable microenvironment for tumor
growth and metastasis [198,199]. Collectively, accumulating evidence alludes to the
importance of CARM1 and regulation of protein arginine methylation in oncogenesis.

39

1.7 Thesis Overview
The work presented within this thesis aims at extending our current understanding
of the role that the arginine methyltransferase CARM1 plays in global transcriptional
regulation. To this end we took a top-down approach in two quite different model
systems, using large-scale ChIP-on-chip and ChIP-Seq approaches in conjunction with
expression microarray analysis to initially identify global effects. We subsequently
refined our observations to specific critical pathways and/or target genes regulated by
CARM1.
Chapter 2 details our assessment of CARM1 as part of a coregulatory complex
with the steroid receptor coactivator p/CIP in an estrogen-dependent transcriptional
context. In this study, we show, using a ChIP-on-chip approach, that in response to
stimulation with E2, a p/CIP/CARM1 complex is recruited to a subset of responsive
promoters in MCF-7 breast cancer cells. Following extensive bioinformatic
characterization, we ultimately focused on Jak2, a member of the JAK/STAT signalling
pathway, and one of the direct E2-dependent targets of p/CIP/CARM1. E2-dependent
histone modifications at the Jak2 promoter reflected recruitment of a functional
p/CIP/CARM1 complex, and were generally transcriptionally permissive. Modest
increases in Jak2 expression were observed, leading us to theorize that an additional
factor(s) may be required for a more substantial transcriptional response. Notably,
however, E2-induced expression of Jak2 was diminished when p/CIP or CARM1 were
depleted, suggesting that the p/CIP/CARM1 complex is required for the observed
transcriptional response. Collectively, the results of this study led us to suggest that E2dependent recruitment of the p/CIP/CARM1 complex causes JAK2 to become ‘poised’
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for transcription, a finding that may be extendable to other target genes and signalling
pathways.
The work we present in Chapter 3 takes a novel approach to characterizing
CARM1-dependent transcriptional regulation. Previous assessment of the role of
CARM1 in gene expression has been primarily focused on its ability to interact with,
methylate, and modulate the function of the transcription factors and transcriptional
regulators with which it interacts. No consideration had been given to the independent
recruitment of CARM1 on a genome-wide scale, and little to the ability of CARM1 to
affect expression by directly modifying the chromatin. For this study, we utilized a
mouse embryonic fibroblast (MEF) model system in which CARM1-dependent gene
regulation could be assessed without limiting its functionality to specialized cellular
programs or particular disease states. Again beginning with a genome-wide approach
[this time using ChIP-Seq], we identified genomic regions to which CARM1 is recruited.
Subsequent characterization of binding events suggests a role for CARM1 in
transcriptional elongation, and implicates the transcription factor PAX1 as a potential
mediator of CARM1 genomic recruitment. When we identified genes that are
differentially expressed when CARM1 is absent, we found that direct recruitment of
CARM1 was not essential for its transcriptional effects. Functional analysis focused us
on a critical role for CARM1 in cellular growth and proliferation, and we showed that in
the absence of CARM1, the expression of many cell cycle regulators is dramatically
altered. When subjected to further replicative stress, cell cycle-compromised, CARM1null cells did not survive.
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Collectively, the work presented herein highlights a few of the mechanisms
through which CARM1 can affect global transcriptional regulation.
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Chapter 2

2

β-Estradiol-dependent activation of the JAK/STAT
pathway requires p/CIP and CARM

2.1 Introduction
Transcriptional activation is a highly dynamic process that involves a large and
diverse class of proteins known as coactivators. Coactivators mediate specific
transcriptional responses by utilizing several interrelated mechanisms involving
chromatin remodeling and covalent modification of histones. These mechanisms often
work cooperatively to alter the structural restrictions imposed by packaging of DNA into
chromatin. Additionally, many coactivators function as adaptors/bridging factors to
recruit additional coactivator proteins to target genes [1]. Detailed genome-wide
chromatin immunoprecipitation (ChIP) studies of binding sites for various transcription
factors, such as the estrogen receptor (ER), have provided significant insight into the
dynamics of coregulator activity at selected targets [2]. For example, the ER undergoes a
cyclic pattern of association and dissociation at selected ER targets [2,12], and its
association with DNA often coincides with the recruitment of several ERα-interacting
complexes. These complexes consist of various combinations of coregulators, the basal
transcriptional machinery, as well as RNA polymerase II [3]. The p/300 CBP interacting
protein (p/CIP), also known as SRC3/AIB1/ACTR/RAC3, [4–9] belongs to a family of
steroid receptor coactivator (SRC) proteins containing two additional family members
(SRC1 and SRC2). p/CIP interacts directly with the liganded ER, and functions primarily
as a bridging factor that binds to hormone-bound nuclear receptors to promote coactivator
complex assembly [10,11]. ChIP assays have established that p/CIP associates with many
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endogenous ER target genes in response to 17β-estradiol (E2), including pS2 [3],
cathepsin D [12] and cyclin D1 [13]. Additionally, p/CIP interacts with other liganded
nuclear receptors [5,7–9] and other classes of transcription factors such as E2F [14] and
NFkB [15].
Several studies have shown that p/CIP undergoes a variety of posttranslational
modifications in response to extracellular signals such as phosphorylation, acetylation,
methylation, ubiquitination, and sumoylation [10,16–20]. These modifications provide an
important regulatory mechanism that defines the combinatorial associations with
additional coactivators, resulting in the formation of diverse multimeric complexes,
which generate distinct gene expression programs. The coactivator-associated arginine
methyltransferase protein (CARM1) is one such coactivating partner that interacts with
the carboxy terminus of p/CIP as well as other SRC proteins. CARM1 has been shown to
methylate proteins involved in RNA processing as well as specific arginines at positions
17 and 26 on histone H3, suggesting that CARM1 plays a direct role in gene transcription
[21,22]. Furthermore, several studies have demonstrated a correlation between
recruitment of CARM1, methylation of histone H3, and activation of several steroid
responsive genes [23–26]. Sequential ChIP analysis has identified a complex consisting
of p/CIP and CARM1 on several estrogen responsive genes [16,27,28], and CARM1
synergizes with p/CIP to activate NR-dependent transcription [29–31]. Collectively, these
studies suggest that direct recruitment of CARM1 by p/CIP represents an essential
activating step for ER-dependent transcription. In the present study, we have used
sequential ChIP–reChIP assays in conjunction with genome-wide microarray screening to
identify E2-dependent gene promoter targets of the p/CIP/CARM1 complex. Importantly,
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our studies identify the JAK2 promoter as a novel target for the p/CIP/CARM1 complex
in response to E2, indicating a novel interplay between ER signaling and the JAK/STAT
pathway at the level of transcription, which may have implications in ER positive breast
cancers where the JAK/STAT signaling pathway is constitutively active.

2.2 Results
2.2.1

Identification of genes directly targeted by the p/CIP/CARM1
complex in response to β-estradiol (E2)
To identify p/CIP/CARM1 target genes which play a role in E2-dependent

signaling we embarked on a genome-wide chromatin immunoprecipitation assay
approach based on DNA Selection and Ligation (ChIP-DSL) [32]. Briefly, MCF-7 cells
were treated with E2 for 45 min and a standard ChIP assay was performed using an
antibody against p/CIP. The immunoprecipitated material was then reChIPed using a
CARM1-specific antibody. The resulting p/CIP/CARM1-enriched and input DNA was
then

purified,

biotinylated,

and

combined

with

40,000

unique

predesigned

oligonucleotides. After annealing, the biotinylated DNA was selected using streptavidin
Sepharose and hybridized to a 20,000 gene promoter array (Figure 2-1A). The
identification of E2-dependent p/CIP/CARM1 targets was based on the following criteria:
first, we established a list of genes displaying a statistically significant enrichment
relative to input (p<0.05) regardless of the treatment. From this list, genes that displayed
a 2-fold or greater enrichment in the E2-treated cells relative to control were identified
(i.e. a twofold or greater enrichment was observed in cells treated with E2 as compared to
the untreated cells). The experiment was performed in triplicate and based on these
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Figure 2-1 ChIP-DSL analysis of p/CIP/CARM1 target genes in MCF-7 cells.
(A) Sequential ChIP-reChIP coupled to DNA Selection and Ligation (ChIP-DSL) was
used to assess global promoter occupancy by the p/CIP/CARM1 complex. Sequential
ChIP-reChIP was performed using either IgG or anti-p/CIP followed by anti-CARM1
antibodies in control and 17β-estradiol stimulated MCF-7 cells. Total input and antibodyenriched DNA were biotinylated and annealed to a 40mer oligonucleotide pool.
Annealed oligonucleotides were selected for with streptavidin-coated metal beads, and
appropriate 40mers are ligated to form an 80mer which is then labelled and hybridized to
the Hu20K array, which contains sequences from 20,000 unique human promoters.
Scatter plots of (B) control and (C) 17β-estradiol stimulated p/CIP/CARM1 ChIP (y axis)
versus input (x axis) from three independent biological replicates, demonstrating a normal
cluster distribution. (D) Venn diagram depicting the overlap in genes enriched from three
independent ChIP-DSL experiments (Rep 1 to 3).
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criteria we identified 204 gene promoters that become co-occupied by p/CIP and CARM1
in response to E2 treatment for 45 min (Figure 2-1B-C & Table B-1). To validate the
ChIP-DSL analysis, we performed independent ChIP–reChIP experiments for a random
set of target genes identified (Figure 2-2). In the majority of cases tested, treatment with
E2 resulted in the simultaneous recruitment of p/CIP and CARM1, indicating that the
false positive rate was extremely low. It should be emphasized that in our experimental
protocol we have identified gene targets for p/CIP/CARM1 as a consequence of E2
treatment; which may include genes directly regulated by the ER, as well as genes
indirectly regulated by the ER through its association with other transcription factors, or
via a nongenomic pathway.

2.2.2

The ER interacts with a fraction of p/CIP/CARM1 target gene
promoters
To better validate our analysis, we compared our results with two previous studies

examining direct E2-dependent ER binding on a genome-wide scale [33,34]. Carroll et al.
discerned 3665 unique E2- dependent ER binding sites using a ChIP–chip Affymetrix
Human tiling array approach [33], while Welboren et al. used a ChIP-Seq approach to
identify 10,205 genome-wide ER-interaction sites [34]. Using the published
chromosomal locations for ER-binding targets identified in these studies, we
distinguished known genes present within and/or adjacent to these genomic sites. Next,
we conducted direct gene-by-gene comparisons of p/CIP/CARM1 targets in our study
with the ER targets identified in each of the previous studies. An important consideration
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Figure 2-2 ChIP analysis of selected direct p/CIP/CARM1 target genes
Control and 17β-estradiol stimulated MCF-7 cells were cross-linked with 1% formaldehyde, and
sequential ChIP-reChIP was performed using either IgG or anti-p/CIP followed by anti-CARM1
antibodies. Recovered DNA was assayed by PCR using primers corresponding to the promoter
regions indicated. Selected target genes shown are pS2, CCNA2, NFKB1, DYRK1A, WBP11,
IL15RA, TGFB1, NEK4, KRAS2, and MAPK4
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for the purposes of this comparison is that while our analysis was restricted to the 1 kb
proximal promoter regions of genes, the studies conducted by both the comparison
groups encompassed binding sites throughout the entire genome. Notably, in each of
studies used for comparative analysis, only a small proportion (4–7%) of ER interaction
sites were located within promoter regions. Nevertheless, our analysis indicated that
65/204 (32%) [33] and 118/204 (58%) [34] (Figure 2-3A) of identified p/CIP/CARM1
complex targets have previously been shown to display ER binding following E2
treatment. Moreover, 59/204 (29%) p/CIP/CARM1 complex targets were ER binding
targets common to both studies, and were therefore considered to be high confidence ER
interactors (Figure 2-3B, Table 2-1).

2.2.3

Binding site enrichment in the promoters of p/CIP/CARM
target gene promoters
Since our p/CIP/CARM1 target genes may include genes directly and/or

indirectly regulated by the ER, we examined 1 kb upstream promoter sequences of the
gene targets for transcription factor binding site enrichment, to discern potential
mechanisms for E2-dependent p/CIP/CARM1 binding. Using a candidate scanning
approach, we conducted a search for enriched motifs within our target gene promoter
sequences. Previous studies have shown that in addition to directly binding ER-binding
elements (EREs) in response to ligand, the ER associates with C/EBP [35], and can also
be targeted to the DNA via interaction with Oct [36,37], Sp1 [38,39] and/or AP-1
[40,41]. Forkhead motifs were also of interest, as evidence has linked the presence of the
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Table 2-1 p/CIP/CARM1 target genes bind the ER.

TLR3
DBC1
LAP3
LDN12

Accession
Number
NM_003265
NM_014618
NM_015907
NM_012129

SLC4A5

NM_021196

PTER
TRAF3

NM_030664
NM_003300

LETM1

NM_012318

GSF4/CADM1
OCA2
SLC26A1
FRMD1
4BP1
CTNND1
CDH7
RAD9B
ECT2
PCSK5

NM_014333
NM_000275
NM_022042
NM_024919
NM_153029
NM_001331
NM_033646
NM_152442
NM_018098
NM_006200

GATM

NM_001482

TUBGCP6

NM_020461

KCTD16

XM_098368

TGFB1
NEK4
RPS4X

NM_000660
NM_003157
NM_001007

STARD4

NM_139164

HRASLS
PKP4

NM_020386
NM_003628

SMARCAL1

NM_014140

Gene ID

Description
Transmembrane receptor
Peptidase
Peptidase
Calcium-independent cell-cell adhesion
Solute carrier family 4, sodium bicarbonate
cotransporter, member 5
Phosphotriesterase related
TNF receptor-associated factor 3/apoptosis
Leucine zipper-EF-hand containing transmembrane
protein 1
Cell adhesion molecule 1/tumour suppressor
Oculocutaneous albinism II
Solute carrier family 26 (sulfate transporter), member 1
FERM domain containing 1
NEDD4 binding protein 1
Catenin (cadherin-associated protein), delta 1
Cadherin 7, type 2
RAD9 homolog B (S. cerevisiae)/DNA replication
Epithelial cell transforming sequence 2 oncogene
Proprotein convertase subtilisin/kexin type 5
Glycine amidinotransferase (L-arginine:glycine
amidinotransferase)
Tubulin, gamma complex associated protein 6
Potassium channel tetramerisation domain containing
16
Growth factor
Enzyme
Ribosomal protein S4, X-linked
StAR-related lipid transfer (START) domain
containing 4
HRAS-like suppressor
Plakophilin 4/cell adhesion
SWI/SNF related, matrix associated, regulator of
chromatin, a-like 1
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CD9
C9orf95
TMEM16F
IVNS1ABP

NM_001769
NM_017881
XM_113743
NM_006469

DDX54

NM_024072

ITPKB
POLR2F
LAMA1
TSHB
RDH10

NM_002221
NM_021974
NM_005559
NM_000549
NM_172037

KCNQ1

NM_000218

KCTD3
PCP4

NM_016121
NM_006198

LRFN4

NM_024036

ABAT
PTPRJ
JAK2
GPR132
HARS
MDS009
POLG
HSD17B12
AKAP13
DPYS

NM_000663
NM_002843
NM_004972
NM_013345
NM_002109
NM_020234
NM_002693
NM_016142
NM_006738
NM_001385

DYRK1A

NM_101395

EDC3

NM_025083

SLC39A10
SAMD3

XM_047707
NM_152552

FLRT2

NM_013231

MGC14156

NM_032906

MXD3

NM_031300

CD9 molecule/cell adhesion
Orf
Transmembrane protein 16F
Influenza virus NS1A binding protein
DEAD (Asp-Glu-Ala-Asp) box polypeptide
54/tranascriptional regulator
Inositol 1,4,5-trisphosphate 3-kinase B
Polymerase (RNA) II (DNA directed) polypeptide F
Laminin, alpha 1/cell adhesion protein
Thyroid stimulating hormone, beta
Retinol dehydrogenase 10 (all-trans)
Potassium voltage-gated channel, KQT-like subfamily,
member 1
Potassium channel tetramerisation domain containing 3
Purkinje cell protein 4
Leucine rich repeat and fibronectin type III domain
containing 4
4-aminobutyrate aminotransferase
Protein tyrosine phosphatase, receptor type, J
Janus kinase 2 (a protein tyrosine kinase)
G protein-coupled receptor 132
Histidyl-tRNA synthetase
DTWD1 DTW domain containing 1
Polymerase (DNA directed), gamma
Hydroxysteroid (17-beta) dehydrogenase 12
A kinase (PRKA) anchor protein 13
Dihydropyrimidinase
Dual-specificity tyrosine-(Y)-phosphorylation
regulated kinase 1A
Homo sapiens enhancer of mRNA decapping 3
homolog (S. cerevisiae)
Solute carrier family 39 (zinc transporter), member 10
Sterile alpha motif domain containing 3
Fibronectin leucine rich transmembrane protein 2/cell
adhesion
PIGY phosphatidylinositol glycan anchor biosynthesis,
class Y
MAX dimerization protein 3
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Figure 2-3 Binding site enrichment analysis of p/CIP/CARM1 target promoter
sequences
(A) Pie charts indicating the proportion of p/CIP/CARM1 target genes that are known to bind
the ER based on comparison with ChIP-chip analysis performed by Carroll et al. (top) and
ChIP-Seq analysis performed by Welboren et al. (bottom). (B) Venn diagram showing overlap
of p/CIP/CARM1 direct target genes (highlighted in blue) with ER-binding sites identified by
ChIP-chip reported by Caroll et al. and identified by ChIP-Seq reported by Welboren et al. 59
p/CIP/CARM1 target genes were common to both the Carroll et al. and Welboren et al.
analysis, and were considered to be high confidence ER-binding targets. (C) Bar graph showing
the number of individual p/CIP/CARM1 target promoters that contain ERE, Sp1, AP-1, FoxA1,

68

FoxA1/ HNF3α motif to ER recruitment [33,42]. When p/CIP/CARM1 target gene
promoter sequences were compared to a background control set of human housekeeping
gene promoters, many enriched putative binding motifs were identified (Table B-2).
While EREs were shown as being significantly enriched among p/CIP/CARM1 complex
promoters, it was not the most prevalent motif when ranked either by p-value or by
enrichment score. Sp1, C/EBP, Oct, FoxA1, and AP-1 motifs were all found to be more
significantly enriched than EREs among the p/CIP/ CARM1 target gene promoters we
identified. Evaluation of these consensus sites within the individual promoter sequences
confirmed the presence and relative abundance of the motifs, with approximately 12% of
target promoters containing one or more EREs, 31% C/EBPα motifs, 24% Sp1, 20% Oct,
10% FoxA1, and 9% contain putative AP-1 sites (Figure 2-3C). Several of the promoters
contain consensus sites for more than one of the considered transcription factors.
EREs occurred simultaneously more often with C/EBP, Oct, and Sp1 motifs
rather than with FoxA1 or AP-1 motifs (Figure A-1). While a negative correlation
between ERE and AP-1 elements has previously been observed [33], our findings are
contrary to previous reports [33,42] in that FoxA1 motifs did not consistently coincide
with the presence of EREs. This discordance is likely due to our exclusive focus on the
proximal promoter, since Kwon et al. also noted limited association of FoxA1 sites with
proximal promoter ER binding events as identified by ChIP-DSL [43]. The overall
enrichment pattern of putative transcription factor motifs did not change for the 59
p/CIP/CARM1 target genes that are considered to be high confidence ER binding targets
(Figure B-2a) or for targets transcriptionally upregulated following E2 treatment (Figure
B-2b).
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Collectively, this analysis demonstrates a consistent pattern of enriched motifs
among p/CIP/CARM1 complex target promoters, and suggests that transcription factor
crosstalk is likely the favored mechanism of E2-dependent p/CIP/CARM1 recruitment at
the proximal promoters of target genes, regardless of ER binding status or transcriptional
state. The presence of EREs suggests that the classical response with direct binding of the
ER is also involved, albeit to a lesser extent.

2.2.4

A proportion of p/CIP/CARM1 target genes are directly
regulated by E2
To correlate p/CIP/CARM1 binding data with the E2-dependent transcriptional

response, we performed gene expression profiling using MCF-7 cells treated with 10 nM
E2 for 12 h. RNA was isolated, reverse transcribed and hybridized to Affymetrix
microarrays. A list of differentially expressed genes from three independent experiments
was generated (p-value<0.05 was used as the cutoff). Based on these criteria, we
identified 396 and 231 genes that were significantly upregulated or downregulated,
respectively, following E2-treatment (Figure 2-4A), consistent with previous expression
profiling studies [43,44]. Comparison of the microarray expression data with the ChIPDSL results determined that 33 (16.2%) targets proximally bound by the p/CIP/CARM1
complex are significantly upregulated, and 8 (3.9%) p/CIP/CARM1 target genes were
downregulated following E2 treatment (Table 2-2). The reliability of this analysis was
confirmed by quantitative real-time PCR (qPCR) analysis of selected genes (Figure 24B). These findings suggests that proximal binding may be more relevant for

70

transcriptionally upregulated genes, and shows that while the p/CIP/CARM1 complex
may have a preferential role in transcriptional activation, it also plays a direct role in the
repression of specific genes.

2.2.5

The JAK/STAT signaling pathway is a central target for
p/CIP/CARM1
Using Ingenuity Pathway Analysis we were able to identify a number of networks

consisting of target genes that are functionally or biochemically linked. Several of the
genes play a role in disease (Figure 2-5A), and the molecular and cellular functions most
associated with p/CIP/CARM1 target genes have been linked to the initiation and
progression of cancer (Figure 2-5B). We found that the network containing one of the
highest number of functionally linked targets is the canonical JAK/STAT signaling
pathway. Several interconnected genes within this pathway are direct targets for p/CIP
and CARM1, including janus tyrosine kinase 2 (Jak2), the interleukin 15 receptor
(Il15ra), and Pias2-a sumo ligase, which functions as a coregulator for STAT proteins
(Figure 2-4C, colored targets). Adding to the implied relevance of p/CIP/CARM1mediated regulation of this pathway, Stat3 and Stat5 (Figure 2-4C, gray targets) were also
identified as E2-dependent p/CIP/CARM1 binding targets, however, they were not
included on the final list as they did not meet the applied statistical criteria. We focused
our initial analysis on the Jak2 gene. JAK2 plays a central role in JAK/ STAT signaling
and mammary gland development, and hyperactivation of this protein is associated with
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cancer initiation. Importantly, functional ablation of JAK2 in mice protects against the
onset of mammary tumorigenesis [45].

2.2.6

E2-dependent regulation of JAK2

JAK2 expression was assessed using qPCR following E2 treatment of MCF-7 cells
for various time periods. We observed an initial decrease in Jak2 expression 1 h
following E2 treatment, and a gradual increase in expression thereafter, such that at 12
and 24 h the expression levels are consistent with preliminary expression array data, with
an approximately 1.5-fold increase in expression when compared to the untreated control
(p<0.05) (Figure 2-4B). Analysis of JAK2 protein levels exhibit a corresponding trend,
with a modest increase (~1.3 fold) in protein expression after 12 and 24 h of E2
stimulation, followed by a decrease to control unstimulated expression levels at 72 h
(Figure 2-4D).
To validate recruitment of p/CIP and CARM1 to specific regions of the Jak2
promoter we performed ChIP assays. For the purposes of this analysis, we used a region
of the promoter that corresponds to a region 787 to 950 bp upstream of the transcriptional
start site (TSS) (Figure 2-6A). An ERE-Sp1 half-site was identified within this portion of
the Jak2 promoter.
Cells were treated with E2 for 45 min and promoter occupancy was assessed by
sequential ChIP assay using specific antibodies recognizing p/CIP and CARM1. In
addition, ChIP assays were performed using an antibody against the ER to assess a
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Figure 2-4 p/CIP/CARM1 target genes are directly regulated by E2.
(A) Differentially expressed genes after E2-stimulation relative to unstimulated control cells. (B)
Realtime RT-PCR analysis of pS2, JAK2, and MAPK4 following stimulation of MCF-7 cells
with 17β-estradiol for 1hr, 3hr, 12hr, and 24hrs. Data is expressed as means and standard error of
the mean from repeated experiments, performed independently (pS2 n=7, JAK2 n=7, MAPK4
n=3). Paired student’s t-test was performed and statistically significant changes from untreated
samples are indicated. (C) Canonical pathway diagram, highlighting statistically significant
p/CIP/CARM1 complex direct targets in color. Targets in grey are bound by p/CIP/CARM1 but
do not meet statistical criteria. (D) Western blot showing JAK2 levels in MCF7 cells following
17β-estradiol stimulation of MCF7 cells for 1, 3, 12, 24, 48, and 72 hrs. Relative abundance of
protein levels at 12, 24, 48, and 72hr time points was quantified by densitometry.
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Table 2-2 Genes directly regulated by the p/CIP/CARM1 complex a
Gene ID
Genes Activated by
E2
NFKB1
MOCOS
JAK2
STARD4
HARS
IGSF4/CADM1
KCTD3
GTF2E2
ZIM3
PDCD8
WBP11
PRKRIR
ZNF567
IVNS1ABP
BMI1
M6PR
HSD17B12
TM4SF8
CCNA2
LAP3
POLR2F
RAD9B
DYRK1A
PCNA
PCP4
ZNF800
PELO
DPH2L2
RFXAP
CLDN12
PIAS2
ELAC1
RDH10

Accession Number

Description

NM_003998
NM_017947
NM_004972
NM_139164
NM_002109
NM_014333
NM_016121
NM_002095
NM_052882
NM_004208
NM_016312
NM_004705
NM_152603
NM_006469
NM_005180
NM_002355
NM_016142
NM_005724
NM_001237
NM_015907
NM_021974
NM_152442
NM_101395
NM_002592
NM_006198
NM_176814
NM_015946
NM_001384
NM_000538
NM_012129
NM_004671
NM_018696
NM_172037

Nuclear factor of kappa light polypeptide gene enhancer
Enzyme
Janus kinase 2 (a protein tyrosine kinase)
StAR-related lipid transfer (START) domain containing 4
Histidyl-tRNA synthetase
Cell adhesion molecule 1/tumour suppressor
Potassium channel tetramerisation domain containing 3
General transcription factor IIE, polypeptide 2, beta 34kDa
Zinc finger, imprinted 3/transcription factor
Enzyme/cell death
WW domain binding protein 11
Protein-kinase, interferon-inducible RNA dependent inhibitor
Transcription factor
Influenza virus NS1A binding protein
BMI1 polycomb ring finger oncogene
Mannose-6-phosphate receptor (cation dependent)
Hydroxysteroid (17-beta) dehydrogenase 12
Tetraspanin 3
Cyclin A2/cell cycle
Peptidase
Polymerase (RNA) II (DNA directed) polypeptide F
RAD9 homolog B (S. cerevisiae)/DNA replication
Dual-specificity tyrosine(Y)-phosphorylation regulated kinase 1A
Proliferating cell nuclear antigen
Purkinje cell protein 4
Unkown
Pelota homolog (Drosophila)
DPH2 homolog (S. cerevisiae)
Regulatory factor X-associated protein
Calcium-independent cell-cell adhesion
Protein inhibitor of activated STAT, 2
ElaC homolog 1 (E. coli)/trna processing
Retinol dehydrogenase 10 (all-trans)

Genes Repressed by E2
PXMP4
NM_007238
Peroxisomal membrane protein 4, 24kDa
HBD
NM_000519
Hemoglobin, beta /// hemoglobin, delta
MAPK4
NM_002747
Mitogen-activated protein kinase 4
ITPKB
NM_002221
Inositol 1,4,5-trisphosphate 3-kinase B
MXD3
NM_031300
MAX dimerization protein 3
MGC15882
NM_032884
C1orf94
LMOD1
NM_012134
Leiomodin 1 (smooth muscle)
CD9
NM_001769
CD9 molecule/cell adhesion
a
Comparative analysis of ChIP-chip data and expression analysis following 12hr E2-stimulation of MCF-7 cells
allowed for the identification of p/CIP/CARM1 regulated genes.

74

possible mechanism of recruitment for the p/CIP/CARM1 complex to the Jak2 promoter.
We found that the p/CIP/CARM1 complex binds in a ligand-dependent manner to the
Jak2 promoter (Figure 2-6B). Importantly, we also determined that the ER binds Jak2 in
response to ligand (Figure 2-6B). The presence of both the p/CIP/CARM1complex and
the ER at the same region of the promoter suggests that E2-dependent complex
recruitment to the Jak2 promoter is mediated through its interaction with the EREassociated ER. This finding is consistent with the putative status of Jak2 as one of the 59
high-confidence ER targets.
To determine whether the E2-dependent assembly of a p/CIP/CARM1 complex
impacts the chromatin marks at the Jak2 promoter, ChIP analysis was performed using
antibodies corresponding to histone modifications associated with transcriptional status;
histone H3 lysine 4 trimethylation (H3K4me3) and acetylation of histone H3 at Lysines 9
and 14 (H3Ac) are modifications generally indicative of transcriptionally active
chromatin structure [46,47]. In addition, CARM1 is known to asymmetrically
dimethylate arginine 17 on histone H3 (H3R17me2), a mark that is also associated with
transcriptional activation [48].
E2-dependent changes in histone modifications were observed at the Jak2 promoter.
In response to treatment, there was a modest increase in acetylation of H3K9 and H3K14
(H3K9/14ac) (Figure 2-6C) and a statistically significant enrichment in dimethylation of
H3R17 (Figure 2-6D), consistent with recruitment of a functional p/CIP/CARM1
complex. Trimethylation of H3K4 remained unchanged by E2 treatment (Figure 2-6C),
perhaps suggestive of a transcriptionally permissive but not fully active gene state, in
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Figure 2-5 Functional classification of p/CIP/CARM1 target gene promoters.
(A) Schematic Ingenuity pathway analysis indicates (A) that cancer is one of the diseases most
commonly associated with the p/CIP/CARM1 target genes and (B) that molecular and cellular
functions associated with the gene set highlights cellular growth and proliferation as
predominating. Adapted from © 2000-2011 Ingenuity Systems, Inc. All rights reserved.
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agreement with the modest E2-dependent increases in mRNA observed (Figure 2-4B). To
determine if the changes in histone modifications are dependent on the presence of p/CIP,
quantitative ChIP analysis was performed on the Jak2 promoter following siRNAmediated gene silencing of p/CIP. p/CIP was present minimally on the promoter despite
p/CIP depletion (Figure 2-7B), likely due to incomplete knockdown (Figure 2-7A). The
level of p/CIP present on the promoter was increased in response to hormone (Figure 27B). The functional effect of p/CIP depletion was determined by ChIP assay evaluating
the presence of the CARM1-dependent histone modification H3R17me2 in response to
E2. As a chromatin mark associated with transcriptional activation, in the absence of
p/CIP [and complex] recruitment, E2-dependent dimethylation of R17 on histone H3 was
reduced (Figure 2-7B), indicating that p/CIP is likely required for recruitment of
CARM1, and its subsequent methyltransferase activity.
To further our understanding of the role that the p/CIP/CARM1 complex plays in
regulating Jak2, we assessed its E2-dependent expression in the absence of p/CIP or
CARM1. When a control siRNA was used, we saw a statistically significant induction of
Jak2 expression, based on realtime PCR, after 12 and 24 h of E2 treatment. However,
when p/CIP was downregulated using siRNA, this effect was diminished (Figure 2-7C).
A similar experiment was performed following CARM1 knockdown and, although the
knockdown was not complete, there was a more dramatic loss of E2-dependent Jak2
expression as compared to p/CIP knockdown (Figure 2-7D). Interestingly, when MCF7
cells were treated with E2, we also observed an increase in Stat3 phosphorylation,
indicative of E2-dependent JAK/STAT pathway activation. However, when either p/CIP
or CARM1 was depleted, this effect was lost (Figure 2-7C & D). Collectively, these data
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suggests that p/CIP and CARM1 are in part required for the E2-dependent regulation of
Jak2 transcription and activation of the JAK/STAT signaling pathway in MCF7 cells.

2.3 Discussion
In the present study, we identified E2-dependent target genes for the p/CIP/CARM1
coregulatory complex. We then determined the transcriptional status of those genes
following 12 h E2 treatment, and compared the lists with known ER binding sites in an
attempt to clarify a mechanism for complex recruitment and subsequent gene regulation.
Global characterization of p/CIP (SRC-3) binding sites conducted by Lanz et al.
identified 12,294 E2-dependent targets using ChIP-Seq, 5512 of which were distinct from
those found using vehicle stimulation [49]. Many of these sites overlap with previously
identified ER binding regions, and, in accordance with accumulating genomic analysis
indicating that the majority of ER binding sites are located in regions far upstream of the
TSS, only a minority (~3%) of E2-dependent p/CIP binding is suggested to occur within
500 bp of the TSS. The level of CARM1 activity (as assayed by its methylation of
H3R17 and/or p/CIP) across the genome also appears to cluster predominantly at a
distance from promoters [50]. These observations of a limited set of proximal promoter
binding sites for p/CIP, and minimal CARM1 methylation activity at promoter elements
correspond with the relatively small number of promoters we identified as interacting
with the p/CIP/CARM1 complex, and is also consistent with proximal ER binding events
previously identified using the 1 kb promoter-specific ChIP-DSL approach [43].
Although now largely superseded by ChiP-Seq, ChIP-DSL is a highly sensitive assay
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Figure 2-6 Characterizing E2-dependent histone modifications to JAK2 proximal
promoter
(A) Schematic representation of the JAK2 1kb proximal promoter, highlighting region used for
ChIP analysis. (B) Control and 17β-estradiol stimulated MCF-7 cells were cross-linked with 1%
formaldehyde, and ChIP or sequential ChIP-reChIP was performed using the indicated
antibodies, followed by qPCR. ChIPs were performed in triplicate, standardized to IgG, and
shown as percentage of Input. Statistical significance was determined using Student’s t-test and
is indicated by * (p<0.05). (C-D) ChIP-qPCR analysis of JAK2 promoter following E2 treatment.
ChIPs were performed in duplicate (H3K9/k14ac, H3K4me3) or triplicate (H3R17me2) using
indicated antibodies, quantitated with real-time PCR, standardized to IgG control and shown as
percentage of Input. Statistical significance was determined using Student’s t-test and is indicated
by * (p<0.05).
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which eliminates some of the biases introduced by more conventional ChIP-on-chip
whole-genome approaches. In ChIP-DSL, the immunoprecipitated genomic DNA is used
only as a template to mediate annealing and ligation of aligned oligonucleotide pairs.
After annealing, the biotinylated DNA is then selected using streptavidin Sepharose and
Taq ligase is used to ligate oligonucleotides positioned directly adjacent to each other,
creating complete amplicons, which are hybridized to a 20,000 gene promoter array. A
limitation of this approach is that analysis is restricted to those promoters found on the
array, which contain 1 kb of upstream regulatory sequence. Studies have shown that the
majority of ER binding sites are found more distal than the proximal promoter.
Nevertheless, promoter proximal interactions do occur in response to E2 and this
interaction can have transcriptional consequences. Furthermore, our study does not
examine ER binding directly, but rather focuses on occupancy of p/CIP/CARM1 in
response to E2. Thus, it would theoretically include those targets that are targeted to
promoter regions by E2 independent of direct DNA binding, and possibly via enhancer–
promoter interactions.
A major advantage of this approach is that we identified 204 promoter-proximal
interaction sites for the p/CIP/CARM1 complex, eliminating the complicated process of
assigning responsive genes to distant binding sites, and instead were able to directly
correlate complex interaction with transcriptional effect. Previous microarray studies with
E2-stimulation can be broadly categorized based on the length of hormone treatment.
There is an observable difference in the pattern of expression change, such that at early
time points (<6 h) more genes are upregulated and more variation is evident between
time points, while at later time points (>12 h) there is a more stable pattern of expression
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change and the majority of genes are downregulated [33,44]. We showed that after 12 h
of stimulation with E2, approximately 20% of p/CIP/CARM1 complex target genes
identified by ChIP-DSL were transcriptionally altered (16.2% upregulated and 3.9%
downregulated). The relatively small number of transcriptionally changed target genes
after 12 h implies that proximal recruitment of the p/CIP/CARM1 complex is not
predictive of E2-dependent gene expression at this late time point. However, among those
targets that are transcriptionally altered, the complex plays a preferential role in
activation, consistent with the role of p/CIP as a coactivator. While the changes in target
gene expression that we observed were modest, we do observe notable changes in
chromatin modifications, suggesting that E2 may facilitate crosstalk.
Direct comparison of target gene promoters in our study with known genomic ER
binding sites in MCF-7 cells [under equivalent E2- stimulation conditions] [33,34]
identified 59/204 (29%) p/CIP/CARM1 complex targets as putative high-confidence ER
binding targets. Therefore, it seems likely that the p/CIP/CARM1 complex is recruited to
this subset of E2-responsive promoters via the ER. We also identified a trend in which
binding motifs for transcription factors known to facilitate ER recruitment were enriched
among p/CIP/CARM1 complex target promoter sequences. While Sp1, C/EBP, Oct,
FoxA1, and AP-1 motifs have previously been shown to be enriched, in addition to
EREs, in the sequences surrounding ER binding events on a genome-wide scale
[33,42,50], there has not previously been much discussion related to the proximal
promoter region or when considering recruitment of an E2-regulated complex. Neither
the predicted ER-binding state nor the transcriptional status of complex target genes after
12 h E2 treatment was predictive of enrichment of transcription factor binding motifs
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Figure 2-7 p/CIP/CARM1 mediated E2-dependent regulation of JAK2
(A) Representative Western blot showing 72hr siRNA depletion of p/CIP in MCF7 cells. (B)
ChIPs were performed in triplicate at JAK2 promoter regions using indicated antibodies,
quantitated by real-time PCR, standardized to IgG control and shown as a percentage of Input.
Data is expressed as means and standard error of the mean from triplicate experiments. (C-D)
Analysis of E2-dependent JAK2 transcription (top) and STAT3 activation (bottom) with siRNAmediated depletion of (C) p/CIP or (D) CARM1. (Top) Realtime RT-PCR analysis of JAK2 was
performed following 12 and 24hr exposure to hormone, and data is expressed as the mean and
standard error of the mean from triplicate experiments, performed independently. Student’s t-test
was used to compare E2-induced expression changes and statistically significant differences from
control samples are indicated. (Bottom) Representative Western blot showing knockdown
efficiency and STAT3 activation in MCF7 cells following E2 treatment.
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studied, and so, consensus mechanisms for differential transcriptional responses as
implied by the recruitment of the ER could not be inferred.
Several of the targets identified are components of the canonical JAK/STAT
signaling pathway. This pathway mediates the activity of a wide variety of cytokines and
growth factors [51]. JAK2 is a central component of the pathway and is responsible for
phosphorylation and activation of the STAT family of proteins, which normally reside in
the cytoplasm and, upon activation, translocate to the nucleus and bind to specific target
genes involved in cell proliferation and survival [51]. JAK2 or STAT5 null mice display
phenotypes remarkably similar to the ERα and p/CIP knockout animals including defects
in mammary gland cell proliferation and apoptosis [52,53]. Importantly, overexpression
or constitutive activation of STAT3 and 5 proteins has been described in many types of
cancers [54] and promote the occurrence of sporadic mammary cancers in mice [45,55–
57]. In proliferating ER-positive tumor cells, E2 is known to stimulate phosphorylation
and activation of STAT3 and 5, although the mechanism has not been fully elucidated
[58–60]. The PIAS family, most notably recognized for their role as coregulators for
STAT proteins, is also of interest as PIAS1 has been shown to sumoylate p/CIP [and
other SRCs], affecting activity and stability in steroid-receptor signaling pathways in
MCF-7 cells [20]. Collectively, these findings suggest that ER signaling and the
JAK/STAT pathway may cooperate in the regulation of mechanisms implicated in
mammary cancers. This cooperation may be mediated, at least in part, through the
p/CIP/CARM1 complex.
We observed recruitment of the p/CIP/CARM1 complex to the 1 kb promoter of Jak2
in response to E2, with a transcriptional upregulation after 12 and 24 h, but no significant
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effect on protein levels with E2 stimulation. Analysis of histone modifications to the
proximal 1 kb promoter revealed an unclear pattern that was predictive neither of
transcriptional activation nor repression. A modest increase in acetylation of histone H3
at K9 and K14 was observed at a region approximately 1 kb upstream of the Jak2 TSS in
response to E2, which coincides with p/CIP/CARM1 complex recruitment, suggestive of
a transcriptionally active gene. In contrast, there was a lack of discernible change in
H3K4me3 in response to E2 at the same promoter region, a modification that would be
expected to be present near the TSS of an actively transcribed gene [61,62]. We suggest
that these changes reflect a promoter that is not necessarily in line with a fully
transcriptionally active state but may instead be permissive, poised for more robust
transcriptional activation, in a process that may require additional signals.
Our study of chromatin modifications was focused to a single time point for E2
treatment. This is based on previous studies showing maximal p/CIP/CARM1
recruitment to the pS2 promoter 45 min after the addition of hormone [16]. Importantly, a
statistically significant E2- dependent increase in H3R17me2 was evident, corresponding
with the region of p/CIP/CARM1 recruitment, suggesting the complex is functional on
the Jak2 promoter. Reinforcing this idea, we noted that following depletion of p/CIP, E2dependent H3R17me2 of the Jak2 promoter was greatly reduced in addition to an
observable loss of p/CIP recruitment. Finally, siRNA mediated depletion of p/CIP
resulted in a reduction in E2-induced transcription of Jak2, with residual E2responsiveness likely due to functional redundancy between SRC family members.
However, depletion of CARM1 caused a more dramatic loss in E2-dependent Jak2
transcription, suggesting that its enzymatic activity is in fact important for the observed
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regulation by the p/CIP/CARM1 complex. CARM1 activity has previously been
associated with the regulation of a subset of the ER cistrome [50], and herein we provide
a specific example of its E2-dependent recruitment, as part of an active coregulatory
complex, to the Jak2 promoter. We also observed an increase in phosphorylated STAT3,
indicative of activation of the JAK/ STAT signaling pathway. While this activation is not
necessarily dependent on Jak2 transcriptional upregulation, this effect was lost following
siRNA-mediated silencing of p/CIP or CARM1.
Collectively, while the changes in E2-dependent H3R17 dimethylation are indicative
of active Jak2 transcription, the other chromatin marks we examined, as well as the
modest response at the RNA and protein levels, were inconsistent with a fully
transcriptionally active promoter. We suggest that an additional signal may be required
for a more robust transcriptional response of the Jak2 gene. In addition, despite the
changes in expression of select genes, the majority of complex targets did not exhibit a
widespread transcriptional response to 12 h E2 treatment, ultimately suggesting that E2
may cause a general “rewiring” of specific signaling pathways, through recruitment of
the p/CIP/CARM1 complex, so that many essential genes become “poised” for
transcription.

2.4 Materials & Methods
2.4.1

Plasmids, antibodies, and reagents
A complete list of primers used can be found in Table B-3 in Appendix B.

Antibodies used in this study are listed in Table B-4 in Appendix B. All of the antibodies
used for these studies are commercial antibodies, with the exception of the p/CIP
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antibody. The method by which this antibody was generated, purified, and tested has
been previously described [4]. 17β-Estradiol (water soluble) was purchased from Wisent.
All siRNA used was purchased from Dharmacon.

2.4.2

Western Blotting
Cells were grown in phenol red-free DMEM, supplemented with charcoal

stripped FBS and antibiotics, and stimulated with 10−7 M E2 for various time periods as
indicated. Cells were washed twice in phosphate buffered saline (PBS), harvested and
lysed in RIPA lysis buffer (~150 µl/60 mm plate) consisting of 50 mM Tris (pH 8.0), 150
mM NaCl, and 1% NP-40, 0.1% SDS and protease inhibitor cocktail. Extracts were
centrifuged for 10 min at 14,000 rpm at 4 °C and the soluble fractions were retained.
Samples were normalized for protein content and were separated by SDS-PAGE,
transferred to nitrocellulose or PVDF membrane and blocked overnight in PBS
containing 0.1% TWEEN-20 and 5% nonfat dried milk. The appropriate antibodies were
then diluted in blocking buffer and the membrane was probed for 2 h at room temperature
with rocking, followed by incubation with secondary antibody for 1 h. Proteins were
detected using ECL according to the manufacturer's recommendations (Amersham).

2.4.3

RNA isolation and real-time PCR
Total cellular RNA was isolated using RNeasy kit (Qiagen). The quality and

quantity of RNA were evaluated by measuring OD 260/ 280. For real-time PCR analysis,
0.2 µg of RNA was reverse-transcribed with TaqMan reverse transcriptase (Applied
Biosystems) using random hexamers to generate cDNA. All amplicons were detected
using the 5′ nuclease (Taqman) assay with 5′ labeled probes. Probes were already
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predesigned and quality tested (Applied Biosystems). Reactions were performed
according to the manufacturer's recommendations (Applied Biosystems) and were run in
replicates of two, in a 96-well format. Each reaction included 18S RNA as a control for
normalization, and reactions lacking cDNA served as negative controls. Two independent
experiments were performed for each gene following treatment with E2, and a mean
value was obtained and compared to the mean expression level of each gene from
untreated cells. Applied Biosystems 7500 Real Time PCR System software was used to
identify cycle threshold (Ct) for each reaction.

2.4.4

RNA microarray analysis
Total RNA was extracted from MCF-7 cells treated with 10 nM E2 for 12 h and

from control, untreated cells. Independent biological triplicates were performed for each
treatment, including control samples. cDNA was prepared from control and treated
samples, labeled and hybridized to HgU133A+2 human affymetrix DNA microarray.
Hybridization, washing, scanning and analysis of genechips were performed at the
University of Western Ontario, London Regional Genomics Centre (London, Ontario,
Canada). An average intensity of each E2-treated sample was compared to the average
intensity for control non-treated samples. Three biological replicates for each array were
processed and the data was transformed using Robust Multi-Array normalization and
values below 0.01 were set to 0.01. Each measurement was normalized by dividing all
measurements in that sample by the 50th percentile. Ratios were then calculated for all
samples against the median of the control samples. A student t-test statistical analysis
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was conducted and false positives were reduced using Benjamini and Hochberg false
discovery rate.

2.4.5

Chromatin immunoprecipitation assay
MCF-7 cells were cross-linked with 1% formaldehyde at room temperature for 5

min. Cross-linking was quenched by immediately washing cells twice with ice-cold PBS
and harvesting in PBS containing PMSF. Cell pellets were lysed in 0.2 ml of cell lysis
buffer (50 mM Tris-HCl [pH 8.1], 10 mM EDTA, 1% SDS, and protease inhibitors) and
incubated on ice for 10 min. Lysates were sonicated to yield DNA fragments ranging in
size from 300- to 1000-bp. Approximately 450µg of the cross-linked, sheared chromatin
solution was used for immunoprecipitation. A small portion of each IP was saved as input
DNA (5%). Supernatants were diluted 10-fold in dilution buffer (20 mM Tris-HCl [pH
8.1], 1% Triton X-100, 2 mM EDTA, 150 mM NaCl, and protease inhibitors) and
immunoprecipitated using a protein A-Sepharose slurry or with MagnaChIP Protein A
magnetic beads.
When using the Protein A-Sepharose slurry, lysates were precleared with 50 µl of
50% slurry protein A-Sepharose containing 2.5 µg of sheared salmon sperm DNA for 2 h
at 4°C. Immunoprecipitation was performed overnight at 4°C with 1.5-4 µg of the
antibodies. 50 µl of protein A-Sepharose containing 2.5 µg of salmon sperm DNA per ml
was added to the solution and incubated for 1 h at 4 °C. Magnetic beads were washed
using PBS with 0.1% Tween-20, incubated with the relevant antibodies for 2.5hrs at 4
°C, and rewashed prior to immunoprecipitation overnight at 4°C. The beads were washed
one time each with wash buffer I (0.1% SDS, 1% Triton X-100, 2mM EDTA, 20mM
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Tris-HCl, 150mM NaCl), wash buffer II (0.1% SDS, 1% Triton X-100, 2mM EDTA,
20mM Tris-HCl, 500mM NaCl), wash buffer III (0.25 M LiCl; 1% NP-40; 1% NaDeoxycholate; 1 mM EDTA; 10 mM TrisHCl) and twice with TE buffer.
Immunoprecipitated material was extracted twice with 150 µl elution buffer (1% SDS-0.1
M NaHCO3). If sequential ChIP was conducted, eluted samples were reImmunoprecipitated overnight at 4°C with 1.5-4 µg of secondary antibodies. Washes and
elution steps were repeated. NaCl was added to the final 150 µl eluate to a concentration
of 200 mM and the cross-linking was reversed by heating at 65 °C overnight. DNA was
purified using Qiagen PCR purification spin columns.
For analysis by conventional PCR, conditions were as follows: initial denaturing
cycle of at 94 °C for 3 min, followed by 40 cycles of 94 °C for 30 sec, ~57 °C for 30 sec
and 72 °C for 45sec, and a final elongation step of 72 °C for 10 min. For experiments
involving E2-stimulation, MCF-7 cells were plated to approximately 90% confluence and
treated with 10-7M E2 for 45 min prior to ChIP analysis.
For some experiments, DNA isolated from ChIP experiments was subjected to
quantitation by real time PCR using Brilliant SYBR green master mix (Stratagene;
600548). Primers were identified using the Primer Express program (Stratagene) and
tested to establish optimum reaction conditions. Reactions were performed in a 25ul
volume according to manufacturer’s recommendations. The reaction was carried out and
measured using Mx3000P realtime instrument. Standard curves were generated using
total input DNA (copy number range: 8X105 to 8X101). The IP and IgG DNA copy
number was calculated by extrapolating their respective Ct value from the standard curve.
The nonimmune IgG copy number was subtracted from IP DNA copy number. The
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resulting IP copy number was initially normalized against the total input DNA by
dividing the IP by input. The average copy number with E2-treated IPs were then
standardized to untreated control IPs, and recruitment represented as a fold-change with
E2-treatment. All measurements were done in duplicate and an average Ct value was
used to calculate copy number. Two independent realtime reactions were done for each
experiment.

2.4.6

ChIP-DSL assay
Chromatin immunoprecipitation coupled to DNA selection and Ligation (ChIP-

DSL) was used to assess global promoter occupancy by p/CIP/CARM1. MCF-7 cells
were cross-linked with formaldehyde and subjected to standard sequential ChIP–reChIP
assay using affinity purified anti-p/CIP and anti-CARM1 antibodies. The procedure for
oligonucleotide annealing, solid phase selection ligation and PCR amplification were
performed exactly as described (Aviva Systems Biology; H20K, Cat# AK-0504). The
antibody-enriched DNA and the total input were biotinylated followed by annealing to
the 40mer oligonucleotide pool. The DNA–oligonucleotide complexes are then selected
by binding to streptavidin-conjugated magnetic beads, while the non-annealed
oligonucleotides are washed away. Correctly paired 40mers are then ligated to form the
corresponding 80mer which is flanked by both universal primer annealing sites (T3 and
T7) giving rise to a complete amplicon. A PCR reaction was then conducted on the
amplicons using fluorescently labeled T7 and regular T3 primers. Total input DNA was
PCR amplified using Cy5 (green) labeled T7 primer and the immunoprecipitated (IP)
sample was amplified using Cy3 (red) labeled T7 primer. The PCR products are co-
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hybridized to the 80mer array (Hu20K) to derive an enrichment ratio for each target.
After hybridization and washing, array slides were scanned on a One Virtek (Bio-Rad)
Chip Reader, and the ArrayVision (v6.0) software package (London Regional Genomics
Centre, London, Ontario, Canada) was used to quantify fluorescence intensity. The ChIP
on chip intensity values were normalized using a Lowess curve, which was fit to the log
intensity versus log-ratio plot and 20% of the data was used to calculate the Lowess fit at
each point. Following normalization, a two-sided student's t-test was conducted where
standard deviation of the replicates was used to calculate a p-value. Fold change was
calculated for each gene using a mean value that was calculated from all three biological
replicates.

2.4.7

Ingenuity Pathway Analysis

Ingenuity Pathways Systems (http://www.ingenuity.com) analysis was employed to
group statistically significant genes. The 204 genes that bound p/CIP/CARM1 directly
and were transcriptionally affected by E2 were considered for Functional Analysis to
identify the biological functions and/or diseases that were most significant to the data set.
A right‐tailed Fisher's exact test was used to calculate a p‐value determining the
probability that each biological function and/or disease assigned to that data set is due to
chance alone.

2.4.8

Promoter Enrichment Analysis
Promoter sequences were identified using Gene2Promoter within the Genomatix

Suite (www.genomatix.de). Input was in the form of gene accession numbers, and
comparison with transcripts that have been mapped to the ElDorado genome yielded
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mapped sequence results and extracted promoters. A defined 1000bp upstream of the
mapped transcriptional start sites were selected for further transcription factor binding
site analysis. To search for enriched consenus motifs within ElDorado extracted promoter
sequences the BIOBASE Knowledge Library was used, making use of MATCH software
and the Transfac database. Searches were performed with the best supported promoters
using the vertebrate non redundant (minFP) profile. Background frequencies were
determined using control set of human housekeeping gene promoters. Optimized matrix
cutoffs and search window positions were used. Significant matrices were found with pvalue<0.001 and Yes/No>1.2.
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Chapter 3

3

Whole Genome Analysis of CARM1 in wildtype and
CARM1-knockout Mouse Embryonic Fibroblasts

3.1 Introduction
Arginine methylation is a prevalent post-translational modification, found on both
nuclear and cytoplasmic proteins, that has been implicated in the regulation of
transcription, signal transduction, RNA processing, and DNA repair [1-4]. Additionally,
defects in arginine methylation are known to be involved in several disease processes
such as cancer [4-6].
The family of proteins responsible for arginine methylation is collectively known as
protein

arginine

methyltransferases

(PRMTs).

Coactivator-associated

Arginine

Methyltransferase 1 (CARM1), also known as PRMT4, is a Type I PRMT that catalyzes
the formation of asymmetrically dimethylated arginines (aDMA) through a
monomethylated intermediate

[7]. CARM1 is unique among the PRMTs in that it

appears to recognize substrates containing a PGM motif (proline, glycine, methionine),
rather than the more common GAR motif recognized by other PRMT family members
[1,2,7,8].
CARM1 was the first of the PRMTs to be shown to function as a transcriptional
coactivator [1], based on its ability to interact with the p160 coactivator GRIP-1 (also
known as SRC2, NCoA2) [1]. It has since been shown to interact with the two other
members of the p160 family, SRC1 and SRC3 (p/CIP) [1]. CARM1 can methylate both
histone and non-histone proteins, and its ability to synergistically enhance transcription of
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steroid-hormone-regulated genes through its methylation of other coregulators such as
p300, p160 family member(s), and of histone H3 has been extensively characterized [912].
CARM1 has been shown to regulate a wide variety of transcriptionally relevant
target genes, in cell cycle control in addition to those involved in hormone-dependent
signaling. For example, in response to DNA damage CARM1 methylates the p300 KIX
domain. This promotes recruitment of BRCA1 by p300 to the p53-responsive promoter
of p21 and promotes p21 transcription and increased expression

[3]. Additionally,

CARM1 is recruited to the promoter of cyclin E1 (CCNE1) in an E2F-dependent manner,
where it functions as a positive regulator of transcription, by methylating histone H3 at
arginines R17 and R26 [13]. Deletion of CARM1 in mice results in embryos that are
small in size, and die late in development or shortly after birth [14]. CARM1 null mouse
embryonic fibroblasts (MEFs), isolated from E12.5 embryos, do not support the
methylation of CARM1 substrates, including histone H3, p300 and PABP1, and are
defective in NR-dependent signalling

[14]. Additionally, NF-kB dependent gene

expression, important for cellular events such as apoptosis, cell proliferation and
differentiation, is also impaired in CARM1-null MEFs [14]. CARM1 has been shown to
form a complex with p300 and NF-kB in vivo, directly interacting with NF-kB, and
enhancing its promoter-specific recruitment. CARM1 also interacts with β-catenin and
positively regulates β-catenin-mediated gene expression, indicated by H3R17
methylation

[15]. CARM1 can also covalently modify components of the core

transcriptional machinery. CARM1 methylates the C-terminal domain of RNA
Polymerase II at a single arginine residue (R1810), creating a docking site for a tudor-
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domain containing effector molecule (TDRD3) and promoting transcription [16]. PAF1c,
part of the transcription elongation complex, interacts with the CARM1-specific
H3R17me2 mark, and affects transcription of CARM1-regulated, estrogen responsive
genes, indicating that PAF1c may act as an arginine methylation effector [17].
CARM1 has also been shown to interact with several oncogenic transcriptional
regulators, suggesting that CARM1 plays a role in cancer. CARM1 levels have been
found to be elevated in aggressive breast tumours [18,19], and in conjunction with
elevated SRC3 plays a role in ERα-‐‑dependent breast cancer cell differentiation and
proliferation [20,21]. Recent studies using large panels of invasive breast cancer samples
suggest that CARM1 has an oncogenic effect in breast cancer, and that its expression is a
predictor of diminished survival, and of poor disease-free survival [18,19]. CARM1 is
also overexpressed in androgen-independent prostate carcinomas, and in colorectal
cancers [18,19,22].
The majority of CARM1 studies have been conducted in cancer cell lines, and
evaluation of the role CARM1 plays in gene regulation has been primarily focused on its
ability to interact with and regulate the function of specific transcriptional regulators with
little consideration given to the recruitment of CARM1 on a genome-wide scale,
unbiased by association with binding partners.
In this study, we use a ChIP-Seq approach in conjunction with expression
microarray to assess the role of CARM1 in genome occupancy and global gene
regulation. We conducted our examination in CARM1 wildtype and knockout mouse
embryonic fibroblasts (MEFs), a system unaffected by genomic instability in which the
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relevance of direct CARM1-dependent gene regulation can be studied. The absence of
any extrinsic signal or disease context is quite novel and allows for a broader
understanding of CARM1 action, without limiting its functionality to specialized cellular
programs or particular disease states. Our characterization of binding events suggests a
role for CARM1 in transcriptional elongation, and implicates the transcription factor
PAX1 as potential mechanism through which CARM1 can be recruited to the genome.
While our findings suggest that direct genomic recruitment of CARM1 is not critical for
its transcriptional and functional effect(s) in an un-induced system, we note a critical
regulatory role for CARM1 in cellular growth and proliferation, showing that in the
absence of CARM1, the expression of many cell cycle regulators is dramatically altered
and cells become sensitized to additional stressors.

3.2 Results
3.2.1

Analyzing genome-wide CARM1 recruitment
To identify global genomic interaction sites for CARM1, we performed ChIP-Seq

in CARM1+/+ MEFs (Figure 3-1A). Approximately 40 million sequenced reads were
obtained and processed to eliminate corrupt, short, and/or highly repetitive sequences,
before being aligned to the mouse genome (MM9). Based on this alignment and using an
FDR of 0.001, 7022 CARM1-dependent peaks were identified. These peaks were
subsequently filtered using the Mann-Whitney (MW) U test as an intra-sample statistic to
remove false peaks based on strand separation, thereby refining the list to include only
high confidence CARM1-enriched regions. Applying a MW p-value of 0.05, we
identified 432 enriched regions. Several of these regions were validated using
conventional ChIP and ChIP-qPCR (Figure 3-2 and Figure C-1). We determined that
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Figure 3-1 Genome-wide identification of CARM1 recruitment sites in MEFs
(A) ChIP-Seq was performed to identify global genomic CARM1 interaction sites. Sequenced
reads were aligned to the mouse genome (MM9) and peaks were called using Partek Genomics
Suite. (B) Pie chart indicating the genomic distribution of FDR0.001 CARM1 peaks. Promoter
was defined as 5kb upstream & 1kb downstream of TSS. (C) Pie chart indicating the genomic
distribution of subset of FDR0.001 CARM1 peaks identified as significantly enriched CARM1
binding regions by Mann-Whitney U test (p < 0.05). Promoter was defined as 5kb upstream &
1kb downstream of TSS. (D) Association between CARM1 and PAF1c. CARM1 was
immunoprecipitated from CARM1+/+ MEFs; immunocomplexes were separated by SDS-PAGE
and probed with either αPaf1c or αCARM1 antibodies (n=2).
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CARM1 binding is fairly frequent and occurs on average every 378 kb in the mouse
genome. However, Mann-Whitney enriched regions of CARM1 binding events were
more sparse, occurring every 6,174kb. The incidence of CARM1-interacting sites and/or
enriched regions showed weak positive correlation with chromosome length (Figure C1).
When CARM1 enriched regions were annotated to neighboring genes, 153 genes
were identified. Interestingly, in some regions, more than one CARM1-binding event can
be associated with the same gene (Figure C-1). This pattern is most prevalent on
chromosome 8 and X (Figure C-1). However, the functional significance of multiple
binding sites is currently unclear.
When we considered the genomic distribution of all 7022 CARM1 binding
events, or of the smaller cohort of 432 MW-enriched regions, we found that the pattern of
peaks and enriched regions is very similar (Figure 3-1B & C). The majority of binding
(66-70%) occurs in intergenic regions, with the remaining 30-34% associated with
intragenic elements, which includes the promoter region, 3’- and 5’-UTRs, and coding
sequence (CDS). Of the intragenic regions, 17-18% of identified CARM1-interacting
sites were found to be promoter-proximal (defined as 5kb upstream and 1kb downstream
of TSS), with a further 16% of binding in the 5’UTR, indicative of a regulatory role for
CARM recruitment. Contrary to our initial expectations, the majority of CARM1-bound
intragenic sites were found to occur within the CDS. These binding events suggest a
potential role for CARM1 in alternative splicing, a function in which CARM1 has
already been implicated through its methylation of several splicing factors

[2].

Alternately, the predominance of CDS binding sites could also be indicative of
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participation by CARM1 in transcriptional elongation. To assess this possibility, we
performed immunoprecipitation experiments in wildtype MEFs using a CARM1
antibody. Subsequent probing for the elongation-associated RNA polymerase-associated
factor 1 complex (Paf1C) revealed that CARM1 can interact directly with Paf1c (Figure
3-1D), suggesting a potential role for CARM1 in transcriptional elongation.

3.2.2

Elucidating the mechanism of CARM1 recruitment
In an attempt to understand the mechanism(s) through which CARM1 is recruited

to the chromatin in the absence of an extrinsic signal, enriched transcription factor (TF)
binding motifs within all 7022 CARM1 binding events were identified. The most
enriched TF consensus motifs were Hunchback (PAX1), ZNF354C, YY1, Gfi, and MZF1
(Figure 3-3A), all of which have been implicated in transcriptional regulation during
development and/ or oncogenesis. Further assessment allowed for the identification of an
enriched de novo motif among peaks (Figure 3-3B). Notably, the motif discovered de
novo bears striking similarity to the PAX1 consensus motif, which was identified as the
most significantly enriched among CARM1 peaks. This concordance suggests that this
may be a preferred TF through which CARM1 is recruited to the genome.
Comparison of CARM1 peaks and individual TF motif occurrences across whole
chromosomes revealed an expected correlation wherein the top 5 enriched TF motifs
frequently coincide with the MW enriched, high-confidence binding regions for CARM1.
When specifically comparing CARM1 MW-enriched binding regions with the locations
of PAX1 motifs, we observed that high-confidence CARM1 regions corresponded with
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Figure 3-2 Quantitative ChIP analysis validating CARM1 occupancy at sites
identified by ChIP-Seq
CARM1 recruitment to Apbb1ip-, Ctnnd2-, Gm7120-, and Raet1d-proximal genomic locations
was tested in CARM1+/+ MEFs using CARM1-/- MEFs as a negative control. CARM1 ChIPs were
standardized to IgG control, and data is represented as mean percent of input and error bars
represent standard error of the mean.
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Figure 3-3 Transcription factor motif enrichment within CARM1 peaks identifies
PAX1 as possible mechanism of CARM1 recruitment
(A) Enriched JASPAR transcription factor binding motifs found among CARM1 peak sequences
identified by ChIP-Seq. (B) 14bp motif predicted using de novo motif discovery in Partek
Genomics Suite. Height of each position indicates the importance of a base at a particular
location. Different colors were used to represent different nucleic acids: G - yellow; T – red; C blue; and A - green. (C) Bar graph contrasting the number of MW enriched regions of CARM1
binding on each chromosome (grey) with the number of corresponding PAX1 consensus motifs
(hatched).
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PAX1 motifs on average 45% of the time (Figure 3-3C). A representative example of this
trend on chromosome 14 is shown in Figure C-2.
Several of the CARM1 enriched regions containing putative PAX1 binding sites
were selected to assess the role of PAX1 in CARM1 genomic recruitment. Regions were
randomly selected from different chromosomes, and in many cases represented different
genomic contexts (ex. promoter-associated, within CDS, and/or intergenic). Quantitative
ChIP analysis was performed in wildtype and CARM1 null MEFs to validate CARM1
binding at these regions (Figure 3-4A). This analysis was repeated following siRNAmediated depletion of PAX1 in wildtype MEFs to determine if CARM1 recruitment is
dependent on the presence of PAX1. When PAX1 was depleted (Figure C-3), there was a
reduction in CARM1 recruitment at analyzed regions (Figure 3-4B), suggesting that
PAX1 may facilitate the binding of CARM1 to a subset of genes.

3.2.3

Identifying CARM1-dependent global transcriptional effects
Gene expression profiling by microarray analysis was performed in both wildtype

and knockout CARM1 MEFs to assess global transcriptional effects of CARM1. Gene
expression profiles for CARM1-/- and CARM1+/+ MEFs were compared with an
unadjusted p-value cutoff of 0.01. Using this approach, we identified 643 genes which
were found to have a 2-fold or greater change in expression; 283 were upregulated, and
360 downregulated in the absence of CARM1 (Figure 3-5A). The findings of the
expression microarray were extensively validated, using both Western blotting and real-
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time RT-PCR analysis to confirm the expression of selected genes (data not shown and
Figure 3-5B).
In general, the expression changes in the absence of CARM1 were modest, with
most up- or down-regulation falling within ±5-fold. The 10 genes showing the greatest
increase and 10 genes showing the greatest decrease in expression in CARM1-/- MEFs as
compared to CARM1+/+ MEFs are given in Table 3-1. Several of these genes have
previously been implicated in a variety of cancers and other diseases, affecting cellular
programs such as growth, proliferation, p53-mediated apoptosis, cellular migration,
attachment, cell signalling, and drug metabolism. However, the range of distinct
processes impacted by these CARM1-regulated genes implies that functional importance
of CARM1 lies in its ability to act as a master regulator of numerous physiological
pathways that can be coopted in disease states.

3.2.4

Changes in gene expression regulated by genomic CARM1
recruitment

To discern targets that may be directly regulated by CARM1 recruitment,
expression microarray data was compared with the ChIP-Seq, so that CARM1 peaks
could be associated with differentially expressed (DE) genes. Differentially expressed
genes were also compared with the smaller list of MW enriched CARM1-binding
regions. CARM1-interacting sites within varying distances of the TSS for differentially
expressed genes were identified (Table 3-2). As previously discussed, more than one
CARM1 peak can be associated with the same gene. This was notably evident when
identifying genes directly-regulated by CARM1, and while 147 differentially expressed
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Figure 3-4 PAX1-dependent CARM1 recruitment
Quantitative ChIP analysis testing CARM1 occupancy at sites identified by ChIP-Seq that contain
PAX1 TF motif. (A) Validation of CARM1 recruitment to noted genomic locations was tested in
CARM1+/+ MEFs, using CARM1-/- MEFs as a negative control. (B) CARM1+/+ MEFs were
transfected using either control siRNA, or an siRNA directed against PAX1, and qChIP analysis
at the indicated regions was performed. CARM1 ChIPs were standardized to IgG control, and
data is represented as mean percent of input and standard error of the mean.
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Table 3-1 Most differentially expressed genes in CARM1-/- MEFs.
Gene Symbol

RefSeq ID

Aspn
Postn
Thbs2
Fam129a
Mmp3
AW551984
Gas6
Dpt
Arhgdib
Plxdc2
Pappa2
Cp
Tmem176b
Tmem176a
Anpep
2610305D13Rik
Prl2c3
Cyp1b1
Pde3b
Peg3

NM_025711
NM_015784
NM_011581
NM_022018
NM_010809
NM_178737
NM_019521
NM_019759
NM_007486
ENSMUST00000028081
NM_001085376
NM_001042611
NM_023056
NM_025326
NM_008486
NM_145078
NM_011118
NM_009994
NM_011055
NM_008817

Fold
Change
-136.352
-118.104
-40.107
-33.4576
-32.6422
-30.314
-27.245
-26.9105
-24.9759
-24.1199
16.9961
20.1459
20.1924
21.6729
22.1114
25.2344
25.6564
25.7046
28.3394
34.6941

Table 3-2 Differentially expressed CARM1-associated genes.

1kb
5kb
10kb
50kb

# CARM1-associated genes
Total*
Unique
92
52
112
58
128
63
340
147

% CARM1-dependent expression
Up-regulated Down-regulated
43
57
46
54
49
51
43
57

*Total # genes counts the same gene(s) more than once if multiple CARM1 peaks are within the noted distance
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genes were found to have one or more CARM1 peak(s) within 50kb, a total of 340 peaks
could be associated with these genes. However, the presence of more than one CARM1
binding event did not affect the degree to which genes were up- or down-regulated. Of
the 147 unique DE genes, 43% were transcriptionally upregulated, and 57%
downregulated (Figure 3-6A), proportions that are consistent with the overall trend of
transcriptional changes following CARM1 loss (Figure 3-5A).
Only 5% of peaks were associated with differentially expressed genes when
CARM1 binding occurred within 50kb of the TSS, and less than 2% if binding was more
proximal [5kb to TSS], suggesting that direct genomic recruitment of CARM1 is not
critical to its transcriptional effects in the absence of extrinsic signal.

3.2.5

Functional consequences of CARM1-dependent global
transcriptional changes
Gene ontology (GO) analysis was performed to more fully characterize the

relevance of CARM1-dependent global transcriptional changes. Enriched functional
groups were reported if they had more than 2 genes represented and GO terms were
grouped according to their relevance in biological processes, molecular functions, or with
respect to cellular component. When GO analysis was conducted on CARM1-dependent
differentially expressed genes, 2454 GO terms were identified. By comparison, when GO
analysis was conducted on the subset of DE genes that had a peak or MW enriched region
within 50kb of the TSS, the number of corresponding terms was substantially reduced
(Figure 3-6B). This observation reinforces our suggestion that CARM1 genomic binding
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events are most likely not required for CARM1-dependent transcriptional or functional
consequences.
Terms were initially ranked based on attribute score, with a higher score
indicating processes that may be of particular importance to the data set, ostensibly those
processes that are influenced most by CARM1. As expected, protein arginine methylation
is notably affected by loss of CARM1, with associated methyltransferase processes
corresponding to 7 of the 10 highest ranked GO terms. Steroid hormone signalling, and
acetylation of histones were also ranked highly; corresponding with the most extensively
characterized cellular functions of CARM1. Both of these functional changes have been
extensively characterized in the literature, and were independently validated in our study
[data not shown].
Taking an alternate approach, enrichment score was used to rank GO terms. A
greater enrichment score suggested that genes in a given functional group were
overrepresented among CARM1-regulated genes. The most prevalent molecular
functions associated with the differentially regulated genes were transcription factor
activity and protein binding, again corresponding with the known roles of CARM1.
Among the associated biological processes, metabolic processes and growth were
identified as two of the most represented functional categories (Figure 3-7A). Growth
characteristics that were affected by the loss of CARM1 included cellular proliferation,
cell cycle, cell shape and adhesion. Based on these findings we assessed differences in
cellular proliferation between wildtype and CARM1 null MEFs. CARM1 null MEFs
proliferated at a reduced rate when compared to wildtype (Figure 3-7B) and were also
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Figure 3-5 Microarray expression analysis of global expression changes in the
absence of CARM1
(A) Proportion of differentially expressed genes in CARM1-/- as compared to CARM1+/+ MEFs.
(B) Realtime RT-PCR analysis of selected differentially expressed genes (p/CIP, Jak2, Fgf10,
p21, CARM1) in CARM1-/- and CARM1+/+ MEFs. Data is expressed as means and standard error
of the mean from repeated experiments, performed independently (n=2 or 3).
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Figure 3-6 Correlating direct genomic recruitment of CARM1 with changes in
expression
(A) Pie chart indicating the proportion of genes differentially expressed in CARM1 null MEFs as
compared to wildtype, which have a CARM1 peak within 50kb of the TSS as identified by ChIPSeq. The percentage of these directly targeted, differentially expressed genes that are up- and
down-regulated is also indicated. (B) Bar chart comparing the number of GO terms represented
among genes differentially expressed (black bars) in the absence of CARM1, with those
differentially expressed genes that have a CARM1 peak (grey bars) or MW enriched region
(hatched bars) associated within 50kb. GO terms are subcategorized into biological processes,
molecular functions, and cellular component.
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shown to have reduced diameter and cell volume (Figure 3-7D).
Expression microarray results implicated CARM1 in the regulation of many
proteins important for the G1 to S phase transition of the cell cycle (Figure 3-8A). To
confirm the critical nature of CARM1 in cell cycle control, the expression of a panel of
cell cycle regulators was assessed (Figure 3-8B). We found that p21 mRNA (Figure 35B) and protein levels (Figure 3-8B) were increased in the absence of CARM1, with p27
similarly upregulated (Figure 3-8B). Downstream of these proteins, CDK-2 protein levels
were undetectable in CARM1 null MEFs. In addition to the ability of p21 and p27 to
inhibit its activity, this CARM1-dependent depletion of downstream factors may suggest
redundancy in regulation. Also consistent with microarray results, we found that RB was
slightly upregulated in the absence of CARM1 (Figure 3-8B). CDK-4 and CDK-6 levels
were not significantly altered (not shown), and while the upstream cyclin dependent
kinase inhibitors p15 and p16 were both shown by microarray to be significantly
downregulated in the absence of CARM1, protein levels were minimal, and we were
unable to confirm this change in expression. To determine if the extensive involvement of
CARM1 in affecting the expression of cell cycle regulators had functional impact, we
subjected wildtype and knockout MEFs to the additional stress of a cell replication
inhibitor, hydroxyurea (HU), and assessed cellular proliferation. When treated with HU,
the proliferation of CARM1+/+ MEFs arrests (Figure 8C). By comparison, the effect of
HU on CARM1-/- MEFs was much more severe. Not only was proliferation inhibited in
the knockout MEFs; cell number was notably diminished with increasing time posttreatment (Figure 8B). The observations that in the absence of CARM1 the expression of
many cell cycle regulators is dramatically altered, and that cells become sensitized to
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additional stressors, suggests an important role for CARM1 in maintaining cellular
growth and proliferation.

3.3 Discussion
In the present study we assessed the role of CARM1 in transcriptional regulation
using a global genomic approach. The importance of CARM1 in transcriptional
regulation is becoming increasingly appreciated, and several studies have assessed
CARM1 activity on a genome-wide scale, as indicated by the presence of asymmetrically
dimethylated histone H3R17

[23], or the presence of coregulators specifically

methylated by CARM1 [24]. Furthermore, our previous work examined the recruitment
of CARM1 as part of a p/CIP/CARM1 coregulatory complex to a subset of E2-dependent
promoters in MCF-7 breast cancer cells

[25]. However, these studies have not

considered CARM1 recruitment in the absence of an extrinsic stimulus or interacting
partners mediating its recruitment.
Herein we present the first direct assessment of genome-wide CARM1
recruitment. Using ChIP-Seq, we identified 7022 genome-wide CARM1 binding events,
and highlighted a subset of 432 statistically enriched, high confidence regions. In
addition, microarray analysis of wildtype and CARM1-null MEFs revealed 643
differentially expressed genes; 147 of these genes were shown to have a CARM1 binding
event occur within 50 kb, and 58 differentially expressed genes have binding that occurs
within 5kb (Table 3-2). Therefore, CARM1 recruitment does not appear to be predictive
of gene expression, at least not in the absence of an extrinsic signal.
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Figure 3-7 Characterizing some of the functional consequences of CARM1 loss
(A) Pie chart representing enrichment of GO terms implicated among genes differentially
expressed in CARM1-/- vs. CARM1+/+ MEFs. Analysis indicates a prevailing role for CARM1 in
biological processes, specifically metabolic processes, and growth, and cellular processes. (B)
The effects of CARM1 on cellular proliferation. The Moxi Z automated cell counter was used to
assess cellular proliferation in wildtype and CARM1-null MEFs as well as (C) cell diameter, and
(D) cell volume.
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Characterization of genomic CARM1 activity in MCF7 cells by Lupien et al.
identified 4088 sites of H3R17 dimethylation in cells that were not treated with E2 [23].
Despite the difference in cell lines between their study and ours, the distribution of
H3R17me2 bears striking similarity to the distribution of CARM1 binding events we
observed. Corresponding to the observation that 55% of dimethylated H3R17 exists in
intergenic regions, we noted that CARM1 also predominates intergenically (66-69%),
where binding events occur some distance from transcriptional start sites.
Another consistent feature of both studies is the prevalence of CARM1 binding
events (19-20%), and H3R17me2 enrichment (~40%) within the coding sequence of
genes [23]. Due to the frequency of CARM1 binding within the coding sequence (CDS),
coupled with previous evidence suggesting that the transcriptional elongation-associated
Paf1c complex interacts with H3R17me2 [17], we assessed whether these two factors
directly interact, and show by co-immunoprecipitation that Paf1c interacts with CARM1
(Figure 3-1D). Wu et al. demonstrated that in the absence of CARM1 and a
corresponding loss of H3R17me2 genome-wide, Paf1c occupancy at E2-dependent
proximal promoters was decreased [17]. We would suggest that this observed loss of
occupancy might, at least in part, be a direct consequence of the absence of CARM1.
Investigation of enriched transcription factor binding motifs within CARM1
binding regions was performed to determine whether a previously unidentified protein
facilitates CARM1 genomic interaction in an un-induced model. Interestingly, of the five
most enriched TF motifs identified in our study, three of them have previously
documented roles in transcriptional repression [26-28]. We found that the most enriched
transcription factor motif among CARM1-binding regions recognized PAX1, and that
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PAX1 motifs correspond with the most statistically enriched, high-confidence binding
regions for CARM1 in 45% of cases (Figure 3-3C). We evaluated and confirmed
CARM1 recruitment at several regions containing PAX1 recognition sites, and
subsequently demonstrated that CARM1 binding at these regions is diminished when
PAX1 was depleted (Figure 3-4). In 2012, CARM1 was reported to interact with PAX7
[29]. Deletion construct analysis conducted by that group revealed the CARM1-binding
region to be found within the paired domain, and suggested that this ability to interact
with CARM1 may be conserved among the paired box domain (Pax) family, all members
of which share this domain [30]. Collectively, this evidence suggests that Pax family
members, may mediate a subset of genome-wide CARM1 recruitment, and herein we
present supporting examples of PAX1-dependent CARM1 recruitment. PAX proteins
function as transcription factors, and are important for many cellular processes during
embryonic development [31]. During development, PAX1 is expressed in the skeleton,
thymus, as well as the 3rd and 4th pharyngeal pouch [31]. Similar to the CARM1
knockout mouse [14], PAX1 null mice have a reduced thymus [32]. In addition, the
PAX1 knockout has abnormalities in development of the tail, vertebral column, sternum,
and scapula [33]. CARM1 has been shown to be important for endochondral bone
formation [34], and CARM1 null mice are much smaller than wildtype counterparts
[14]. The similarities between PAX1 and CARM1 knockout mice suggest a potential
overlap in developmental regulatory roles. It is likely that the role of PAX1 in recruiting
CARM1 to the genome is relevant only during developmental stages, since its expression
is generally limited to this stage [30,35].
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Figure 3-8 CARM1-dependent regulation of the cell cycle proteins.
(A) Overview of proteins involved in the G1-S phase transition of cell cycle, adapted from Cell
Signalling Technology. (B) Western Blot analysis analyzing the expression of cell cycle
regulatory proteins (p21, p27, CDK-2, RB) in CARM1-/- and CARM1+/+ MEFs. Vinculin was
used as a loading control, and representative images are shown from at least two independent
replicates. (C & D) The Moxi Z automated cell counter was used to assess cellular proliferation in
(C) wildtype and (D) CARM1-null MEFs following treatment with 0.1 mM hydroxyurea (HU).
MEFs were seeded 24hrs prior to exposure to HU, and proliferation was assayed following 24
and 48hrs of HU exposure. Data is expressed as a bar chart, depicting the mean and standard error
of the mean from two independent experiments.
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Functional analysis revealed cellular growth to be one of the primary biological
processes affected by CARM1 loss (Figure 3-7A). Consistent with this result, we showed
that CARM1-/- MEFs proliferate at a reduced rate when compared with CARM1+/+ MEFs
(Figure 3-7B). Furthermore, the CARM1-null cells were smaller in diameter and had a
reduced cell volume (Figure 3-7 C & D). These observations are consistent with our
findings that a substantial number of genes involved in cell cycle control were
differentially expressed in the absence of CARM1 based on microarray analysis (Figure
3-8A). Cell growth in MCF-7 cells that are depleted of CARM1 has been shown to be
reduced [13]. These cells have a corresponding increase in E2F1, and recruitment of
CARM1 to the E2F1 promoter is evident [13]. Previous studies also reveal that CARM1
is recruited to the promoter of the cell cycle regulator cyclin E1, which it positively
regulates in response to E2 [36]. While cyclin E1 and E2F1 are relatively downstream
proteins in the signalling cascade that controls G1-S phase transition in the cell cycle, we
notably observed CARM1-dependent differential expression in several of the more
upstream regulators (Figure 3-8A). The cyclin-dependent kinase inhibitors p21 and p27
were both upregulated in the absence of CARM1, and CDK-2 expression is also
diminished (Figure 3-8B). While our ChIP-Seq did not reveal CARM1 binding events in
the promoters of p21 or p27, this does not exclude the possibility that these genes could
be directly targeted by CARM1 in an induced system. Alternatively, these cell cycle
regulators may be modulated by CARM1-dependent changes in TF and/or coregulator
activity. For example, a mechanism for the regulation of p21 involving CARM1 has been
previously characterized, wherein p53 and BRCA1 cooperate with p300 and CARM1 in
response to DNA damage to induce expression of p21 [3]. Further demonstrating the
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critical nature of CARM1-dependent changes in the expression of cell cycle proteins, the
addition of a stressor in the form of hydroxyurea (HU) to the compromised cell cycle of
the CARM1-/- MEFs resulted in substantial loss of cell viability (Figure 3-8D) as
compared to the proliferative pausing seen in the uncompromised wildtype MEFs (Figure
3-8C).
This study represents the first direct assessment of CARM1 recruitment on a
genome-wide scale. We describe a pattern of CARM1 binding consistent with other
transcriptional regulators, and suggestive of involvement in transcriptional elongation.
Furthermore, we identify PAX1 as a novel interacting protein for CARM1 and a likely
mechanism for CARM1 recruitment during development. Finally, while direct
recruitment of CARM1 does not appear to be essential for the transcriptional change(s)
observed, regulation of cellular growth and proliferation appear to be critically regulated
by CARM1.

3.4 Materials and Methods
3.4.1

Cell Culture and Reagents
The generation of CARM1-/- mice, and extraction of MEFs has been previously

described [14]. CARM1-/- and age-matched wildtype (CARM1+/+) MEFs were cultured
in Dulbecco’s Modified Eagle Medium (Wisent), supplemented with 10% Fetal Bovine
Serum (Wisent), and penicillin/streptomycin (Wisent), and maintained at 37°C and 5%
CO2. All siRNA used in this study was purchased from Dharmacon, and transfection
protocol was followed according to the manufacturer’s recommendations. Cellular
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growth characteristics were assessed using the Moxi Z automated cell counter (ORFLO
Technologies). Hydroxyurea (HU) was purchased from Sigma (catalogue No.127-07-1).
For cell proliferation assays, 106 cells were seeded in 6-well plates, allowed to attach for
24hrs and then trypsinized and counted every 24hrs over 4 days. HU was added 24hrs
post-seeding, and trypsinizing-cell counting cycles were started 24hrs later.

3.4.2

Protein Extraction and Western Blotting

Cells were harvested in RIPA lysis buffer, consisting of 50mM Tris (pH 8.0), 150mM
NaCl, 1% NP-40, 0.1% SDS, and protease inhibitor cocktail. Extracts were incubated on
ice for 10 min and cleared by centrifugation for 10 min at 15,000 rpm at 4°C. Protein
concentrations were determined, normalized, and proteins separated by SDS-PAGE,
transferred to PVDF membrane, and blocked overnight in PBS containing 0.1% Tween20 and 5% nonfat dried milk, or with TBS containing 0.1% Tween-20 and 5% BSA.
Membranes were probed with specific primary antibodies for 2 hrs at room temperature,
followed by incubation with horseradish peroxidase-conjugated secondary antibodies for
1 hour. Signals were detected using ECL according to the manufacturer’s
recommendations (Amersham). Affinity purified anti-p/CIP antibody was generated as
previously described [37,38]. All other antibodies used were commercially purchased:
CARM1 (Bethyl A300-421A and Epicypher 13-0006), SMAD2/3 (Santa Cruz sc-6202),
p21 (Santa Cruz sc-6246), p27 (Santa Cruz sc-528), CDK-2 (Santa Cruz sc-6248), PAF1c
(Bethyl A300-173A). An antibody recognizing RB (Santa Cruz sc-7905) was generously
provided for our use by Dr. Fred Dick (UWO).
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3.4.3

RNA Isolation and real-time PCR
Total cellular RNA was isolated using RNeasy kit (Qiagen) in accordance with

the manufacturer’s directions. The quality and quantity of RNA was evaluated based on
relative absorbance at OD 260/280. For quantitative real-time PCR analysis, 2µg of RNA
was reverse transcribed using the High Capacity cDNA Reverse Transcription Kit
(Applied Biosystems). Amplification was detected using predesigned and quality tested
5’ nuclease Taqman probes (Applied Biosystems). Reactions were performed in
accordance with manufacturer’s recommendations and technical duplicates were run in a
96-well format using StepOne Plus Real-time PCR System (Applied Biosystems). Gene
expression levels were determined based on the cycle threshold (Ct) and 18S ribosomal
RNA was used for normalization. Reactions in the absence of cDNA served as negative
controls.

3.4.4

Expression Microarray
Total RNA was extracted from CARM1+/+ and CARM1-/- MEFs, as described

above. Duplicate experiments were performed. cDNA was prepared from each sample,
labeled, and hybridized to Mouse Gene 1.0 ST arrays. Hybridization, washing, scanning,
and analysis of gene chips were performed at the University of Western Ontario, London
Regional Genomics Centre (London, Ontario, Canada). Probe level data was generated
and summarized to gene level data in Partek Genomics Suite and adjusted for
background. A 1-way ANOVA was performed contrasting expression in CARM1-/- and
CARM1+/+ MEFs and a list of genes that showed a 2-fold or greater change in expression
with an unadjusted p-value of 0.01 was generated.
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3.4.5

Chromatin Immunoprecipitation and ChIP-Seq
CARM1+/+ and CARM1-/- MEFs were cross-linked with 1% paraformaldehyde at

room temperature for 10 min. Cross-linking was quenched by washing cells twice with
ice cold PBS containing PMSF. Cell pellets were lysed in lysis buffer (50mM Tris-HCl
[pH 8.1], 10mM EDTA, 1% SDS, and protease inhibitors) and incubated on ice for 10
min. Lysates were sonicated to yield chromatin fragments approximately 300bp – 1000bp
in length, and ChIP experiments were performed as previously described [25,39], using
antibodies against CARM1 and IgG (2-8µg).
Immunoprecipitated DNA was purified using QIAquick PCR Purification Kit
(Qiagen), and was analyzed either by conventional end-point PCR, or by quantitative
PCR following ChIP (qChIP), as previously described

[25,39]. Quantitation was

performed on a StepOne Plus Real-time PCR System (Applied Biosystems). The signal
from IgG ChIP experiments was subtracted from the signal obtained using the specific
antibody.
The chromatin immunoprecipitation assay used prior to deep sequencing analysis
was modified such that sonication conditions produced genomic fragments in the 250350 bp range. The isolated DNA was sequenced at the University of British Columbia
(http://www.cmmt.ubc.ca/facilities/services/sequencing) using the Illumina sequencing
platform. The obtained reads were then aligned to the mouse genome (MM9) in Partek
Flow using Bowtie (version 0.12.7). Peaks were called using 125bp window in Partek
Genomics Suite. Primers used for ChIP experiments are listed in Appendix C.

125

3.4.6

Transcription Factor Motif Enrichment Analysis
Partek Genomics Suite was used to identify enriched TF binding motifs within

CARM1 binding regions. Briefly, peak sequences were scored against motif models from
the JASPAR database (http://jaspar.cgb.ki.se/). Motif instances within CARM1 peaks
were called if their score exceeded 0.7 sequence quality. CARM1 bound sequences were
also interrogated using Partek Genomics Suite to identify a de novo binding motif using
the Gibbs motif sampling method [40]. A 14bp de novo binding motif was identified by
this approach CARM1 peak sequences.

3.4.7

Gene Ontology Analysis
GO analysis was performed using Partek Genomics Suite. Enriched functional

groups were identified using Fischer’s Exact. Functional groups were reported if 2 or
more genes were represented. Gene Ontology default background file (Mus musculus2012-11-19-MoGene-1_0-st-v1) was used for gene background correction.
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Chapter 4

4

General Discussion

4.1 Thesis Summary
The focus of this thesis is the role of CARM1 in global gene regulation. CARM1
is known to methylate a wide array of proteins important for transcription, including
transcription factors, coregulators, and components of the core transcriptional machinery
[1-3]. However, its characterization to date has been limited by an emphasis on its ability
to interact with and regulate the function of specific transcriptional regulators on a geneby-gene basis and in response to extrinsic signals [4-6]. In Chapter 2, I extend the current
understanding of CARM1 in one of its more well-defined roles, as a secondary
coregulator in E2-dependent gene expression. Using a global genomic approach, I have
characterized its participation as part of a coregulatory E2-dependent p/CIP/CARM1
complex, identifying a subset of gene promoters to which this complex is recruited in
response to E2 [7]. I focus on the recruitment of a functional p/CIP/CARM1 complex to
the proximal promoter of Jak2, and demonstrate that complex recruitment leads to
transcriptionally permissive changes in histone modifications.
In Chapter 3 I identify the genomic sites with which CARM1 interacts in a
specific cell system irrespective of binding partner(s) and in the absence of induction.
This characterization of global CARM1-binding events suggests a role for CARM1 in
transcriptional elongation. Additionally, I have identified the PAX1 transcription factor
as a potential binding partner for CARM1 based on the inability of CARM1 to bind
regions containing PAX1 consensus motifs following siRNA-mediated depletion of
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PAX1. Functional analysis of CARM1-dependent genes implicates a critical role for
CARM1 in cellular growth and proliferation. CARM1 has previously been shown to
affect cell growth [8], and affect specific cell cycle regulators [8-10]. I demonstrate that
hydroxyurea treatment of wildtype MEFs, in which cell cycle proteins are expressed
normally, results in proliferative pausing. By comparison, in CARM1 null MEFs there
are widespread changes in the expression of cell cycle regulators and hydroxyurea
treatment results in loss of viability, suggesting a role for CARM1 in sensitizing cells to
cell cycle stress.

4.2 p/CIP/CARM1 Complex Recruitment
p/CIP is a well validated nuclear receptor coactivator that has been shown to
associate with numerous ER-dependent promoters including the pS2 (also known as
TFF1) in response to E2 treatment in MCF-7 cells [11]. p/CIP is known to act as a
scaffold protein, and facilitate the assembly of coregulatory complexes

[11,12]. In

addition, p/CIP and CARM1 have been shown to synergistically coactivate transcription
[13]; and subsequent studies showed by sequential ChIP analysis that a p/CIP/CARM1
complex is recruited to pS2, facilitating its transcriptional activation [4,5].
Using a ChIP-DSL approach, 204 additional proximal promoters to which the
p/CIP/CARM1 complex binds in response to E2 were identified (Table B-1). Although
ChIP-DSL technology is now outdated, the assay is highly sensitive, and eliminates many
of the biases of the ChIP-on-chip whole-genome tiling arrays more commonly used at the
time. ChIP-DSL was described in 2007 [14]. This technique uses immunoprecipitated
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DNA only as a template to mediate annealing and ligation of aligned oligonucleotide
pairs, instead of directly amplified DNA for hybridization. Adjacent oligonucleotide pairs
ligate to form complete amplicons, which corresponding to regions from unique gene
promoters. The use of unique promoter sequences eliminates potential interference from
repetitive or related sequences during amplification. The primary limitation of this
approach is that analysis is restricted to the 1 kb of upstream regulatory promoter
sequence of genes found on the array. However, a major advantage of the approach is
that targeted sequences are directly associated with known genes, thereby eliminating the
complicated process of assigning responsive genes to distant binding sites.
In 2010, global E2-dependent binding sites for p/CIP were identified [15]. This
study suggested that only a minority (~3%) of E2-dependent p/CIP binding occurs within
500 bp of the TSS, a finding that is consistent with accumulating genomic analysis
indicating that ER primarily interacts with regions some distance (>10kb) from the TSS
[16,17]. In addition, the level of CARM1 activity (as assayed by its methylation of
H3R17 and/or indirectly p/CIP binding [based on recognition of arginine-methylated
p/CIP], across the genome also appears to cluster predominantly upstream of the 1kb
promoter region [18]. Despite the fact that genomic binding of these factors is becoming
increasingly understood to be more prevalent outside of the promoter context, promoter
proximal interactions do occur in response to E2 and these binding events can have
transcriptional consequences. Our discovery of 204 E2-dependent target promoters for
the p/CIP/CARM1 complex corresponds with the observations of a limited set of
proximal promoter binding sites for p/CIP, and with the evidence of minimal CARM1
methylation activity at promoter elements.
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Both p/CIP and CARM1 have been implicated in aggressive breast cancer [1921], with demonstrated roles in E2-induced proliferation of the MCF-7 breast cancer cell
line [22-24]. Ingenuity Pathway Analysis conducted on the identified p/CIP/CARM1
targets implicated a notable proportion of these genes as having an involvement in
cancer, with several cancer initiation- and progression-related molecular and cellular
processes ranking highly (Figure 2-5). Collectively, these data suggests that while
promoter-proximal recruitment of E2-dependent transcriptional regulators is rare,
recruitment of the p/CIP/CARM1 complex to a subset of promoters is likely functionally
relevant.

4.3 Transcriptional
effect
of
the
p/CIP/CARM1 complex recruitment

E2-dependent

Past studies featuring microarray analysis following E2-stimulation of MCF-7
cells can be broadly categorized based on the length of hormone treatment. There is an
observable difference in the pattern of expression change, such that at early time points
(<6 h) more genes are upregulated and more variation is evident between time points,
while at later time points (>12 h) there is a more stable pattern of expression change and
the majority of genes are downregulated [16,25]. We examined changes in mRNA
expression following 12 h of stimulation with E2, and showed that approximately 20% of
p/CIP/CARM1 complex target genes identified by ChIP-DSL were transcriptionally
altered (16.2% upregulated and 3.9% downregulated). The relatively small number of
differentially expressed target genes after 12 h suggests that proximal recruitment of the
p/CIP/CARM1 complex is not predictive of E2-dependent gene expression at this late
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time point. However, that does not necessarily mean that the p/CIP/CARM1 complex is
not active in regulating transcription. Transcription of protein coding genes is primarily
performed by RNAPII

[26]. As an alternate method of determining immediate

transcriptional response assessment of RNAPII recruitment to proximal promoters in
response to extrinsic signal, and corresponding to coregulator or transcription factor
recruitment, is suggestive of active gene expression

[16,17]. When the list of

p/CIP/CARM1 complex targets is compared with RNAPII-bound promoters [16], 86/204
(42%) genes were bound by both p/CIP/CARM1 and RNAPII in response to E2. This
observation supports the suggestion that proximal promoter recruitment may be more
relevant for more immediate transcriptional response. A recently developed technique,
‘Global Run-On Sequencing’ (GRO-seq), would allow for further confirmation that
p/CIP/CARM1 plays a role in rapidly inducing gene expression. This assay maps the
position, amount, and orientation of transcriptionally engaged RNA polymerases
genome-wide [27]. GRO-seq analysis following E2 treatment was recently published and
showed that E2-signaling regulates a large proportion of the transcriptome, and
demonstrated that intergenic ER binding is transcriptionally relevant [28]. Unexpectedly,
the observed transcriptional effects were revealed to be quite transient, suggesting that
longer E2 treatment times previously utilized to allow for mature mRNA accumulation
likely have not provided a comprehensive understanding of E2-dependent transcriptional
regulation.
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4.4 CARM1 is the functional component of p/CIP/CARM1
complex
Several studies have demonstrated a correlation between recruitment of CARM1,
methylation of histone H3, and activation of several steroid responsive genes [29-31].
The methyltransferase activity of CARM1 is critical for this ability to enhance
transcriptional activation by NRs and p160 coactivators [32]. Interestingly, methylation
of H3R17 and/or p/CIP has been detected at 70% of the ER cistrome in MCF-7 cells, and
CARM1 activity genome-wide was found to be predictive of ‘active’ ER sites [18].
Importantly, we noted a statistically significant E2-dependent enrichment in
H3R17me2 on the Jak2 promoter, corresponding with p/CIP/CARM1 recruitment,
suggesting the complex [and specifically CARM1] is functional (Figure 2-6). Reinforcing
this suggestion, we observed a decrease in E2-dependent H3R17me2 of the Jak2
promoter following depletion of p/CIP, as well as a reduction in E2-induced transcription
of Jak2 (Figure 2-7). Depletion of CARM1 caused a more dramatic loss in E2-dependent
Jak2 transcription, suggesting that its enzymatic activity is in fact important for the
regulation of Jak2 by the p/CIP/CARM1 complex. JAK2 is a central component of the
Jak/Stat signalling pathway and is responsible for phosphorylation and activation of the
STAT family of proteins, which normally reside in the cytoplasm and, upon activation,
translocate to the nucleus and bind to specific target genes involved in cell proliferation
and survival [33]. JAK2 null mice display phenotypes similar to the ERα and p/CIP
knockout animals including defects in mammary gland cell proliferation and apoptosis
[34,35]. Furthermore, E2 is known to stimulate phosphorylation and activation of STAT3
and 5, although the mechanism has not been fully elucidated [36-38]. We demonstrate a
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reduction of E2-indced STAT3 phospohorylation following siRNA-mediated depletion of
p/CIP and/or CARM1 (Figure 2-7), suggesting that targeting of JAK2 by the
p/CIP/CARM1 complex may contribute to E2-dependent modulation of this signalling
pathway.

4.5 Characterizing genome-wide CARM1 binding
In Chapter 3 I describe our analysis of global CARM1 recruitment in MEFs. The
use of CARM1 wildtype and knockout MEFs provides a physiologically normal cell
system in which the relevance of direct CARM1-dependent gene regulation can be
studied. Conducting such an examination in the absence of any extrinsic signal is novel
and allows for a broader understanding of CARM1 action, without limiting its
functionality to specialized cellular programs or particular disease states. This study
represents the first time that CARM1 binding has been directly considered on a genomewide scale. Using ChIP-Seq, 7022 CARM1-dependent peaks were identified, and using
statistical filtering methods 432 high-confidence binding regions were delineated.
Analysis of the distribution of binding events revealed a predominance of binding events
occurring at regions distal from the TSS of genes (Figure 3-1). Approximately 6% of
CARM1 peaks correspond to promoter regions (defined as 5kb upstream and 1kb
downstream of TSS), representing 421/7022 peaks. The observation that only a small
proportion of recruitment occurs within the proximal promoter has become a consistent
feature of the genome-wide characterization of transcriptional regulators. The existence
of primarily distal binding sites raises the question of how such binding events can
influence transcription. Technologies have evolved to address these questions, and the
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use of ‘chromosome conformation capture’ (3C) and/or ‘chromatin-interaction analysis
by paired end tag sequencing’ (ChIA-PET) have established a paradigm of chromosomal
looping that brings distal ER binding sites into contact with TSS [39,40]. Importantly,
RNAPII occupancy is enriched at genes where looping occurs [40], suggesting that this
mechanism of bringing distal regulatory elements into contact with the TSS is
functionally relevant for transcriptional control. Hah et al. later demonstrated that, in
addition to this looping, a class of primary transcripts (eRNA) is expressed from ERassociated distal enhancer regions [41]. Future work to assess whether looping events
bring CARM1 into contact with TSS would supplement our understanding of its role in
regulating transcriptional initiation. An additional avenue to be pursued, which will more
fully clarify CARM1’s transcriptional relevance, will be to characterize the global
deposition of the CARM1-dependent histone modification, H3R17me2, by ChIP-Seq.
The presence of H3R17me2 is reflective of CARM1 activity, and will provide insight
into the mechanism of CARM1 action at different genomic locations.
We have previously demonstrated that E2-dependent interaction of CARM1 with
the genome can be mediated through p/CIP [and the ER] [7]. Additionally, CARM1 is
known to be recruited in a complex with transcription factors such as E2F1 [8], β-catenin
[42], and NF-kB [43]. In an attempt to identify other transcription factors that may
facilitate CARM1 binding, we used a bioinformatic approach and assessed the
enrichment of TF binding motifs present within identified CARM1 peaks. The five most
enriched TF motifs were found to correspond with Hunchback (PAX1), ZNF354C, YY1,
Gfi, and MZF1 (Figure 3-3A). Notably, YY1 has been shown to recruit PRMT1, a
CARM family member, to activated promoters [44]. This does not necessarily suggest
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that a CARM1-YY1 interaction exists. However, since the central (methyltransferase
region) of CARM1 shares a high degree of homology with PRMT1 [13,32], it seems
possible that a similar, albeit context-dependent, association with YY1 may occur. Our
experimental focus, however, was on the most enriched motif, PAX1. De novo motif
discovery produced a strikingly similar motif to the PAX1 consensus site (Figure 3-3B).
Next, we validated using quantitative ChIP analysis that CARM1 was binding at regions
containing PAX1 motifs (Figure 3-4A). Ultimately, the strongest evidence suggesting
that PAX1 may facilitate CARM1 genomic recruitment came from the observation that
when PAX1 was depleted using siRNA, there was a reduction in CARM1 enrichment at
analyzed regions (Figure 3-4B). While this is the first evidence that PAX1 may facilitate
genomic recruitment of CARM1, it is not the first time CARM1 has been shown to
interact with the paired box (Pax) protein family. CARM1 has been shown to interact
with PAX7 [45], with the CARM1-binding region present within the paired domain.
Taken together, these findings suggest that the ability to interact with CARM1 may be
conserved among the paired box domain (Pax) family. It is likely that the role of PAX
proteins in recruiting CARM1 to the genome is relevant only during developmental
stages, since their expression is generally limited to this stage [46,47].

4.6 CARM1 in Transcriptional Elongation
Arginine methylation of transcriptional elongation factors by PRMT family
members has been previously demonstrated, with PRMT1 and PRMT5 affecting
association between SPT5 and RNAPII, resulting in transcriptional pausing [48]. In
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addition, PRMT7 can symmetrically dimethylate eukaryotic elongation factor 2 (eEF2)
[49]. The evidence linking CARM1 with transcriptional elongation has been more
indirect. Several components of the transcriptional elongation-associated Paf1c complex
have been shown to interact with the CARM1-specific histone modification H3R17me2
[50]. CARM1 can also methylate the C-terminal domain of RNAPII, and contribute to
transcriptional activation by creating docking sites for effector protein(s) [3].
Our assessment of the genomic distribution of CARM1 peaks revealed that 20%
(1404/7022) of binding events occurred within gene bodies (Figure 3-1). These binding
events could reflect a role for CARM1 in alternative splicing and mRNA processing, a
function in which CARM1 has already been implicated through its methylation of several
splicing factors [51]. Alternately, the predominance of binding sites within the CDS of
genes could also be indicative of a direct role for CARM1 in transcriptional elongation.
To address this possibility, we performed co-immunoprecipitation experiments in
CARM1+/+ MEFs and demonstrated an interaction between CARM1 and Paf1c (Figure 31D). Furthermore, we attempted to discern an association between CARM1 and activated
RNAPII, however these experiments are currently ongoing. Taken together, the
predominance of CDS binding sites and the demonstration that CARM1 directly interacts
with the elongation-associated Paf1 compex presented within this thesis provides
evidence to support the involvement of CARM1 in transcriptional elongation. Future
work will need to be conducted to fully elucidate its regulatory role in this stage of gene
expression.
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4.7 Functional Impact of CARM1
Functional analysis of the genes targeted by the p/CIP/CARM1 coregulatory
complex implicated cancer as one of the primary diseases affected by their misregulation.
Furthermore, processes including cellular growth and proliferation, development, cell-tocell signaling, and morphology were associated with this gene set (Figure 2-5). It is
interesting to note that when functional analysis is conducted on genes differentially
expressed in the absence of CARM1, similar cellular processes were implicated (Figure
3-7). Since sustained proliferation is one of the most fundamental characteristics of
cancer cells [52], and functional analysis implicated growth characteristics as being
critically regulated by both CARM1- and p/CIP/CARM1-regulated genes, we further
analyzed the impact of CARM1 in this process.
CARM1 has been previously implicated in growth as well as cell cycle control.
CARM1 knockout mice are small in size, and NF-kB dependent gene expression,
important for cellular events such as apoptosis, cell proliferation, and differentiation, is
impaired in CARM1-null MEFs [53]. CARM1 also plays a role in ERα-‐‑dependent breast
cancer cell differentiation and proliferation

[24,54]. In response to DNA damage

CARM1 methylates the p300 KIX domain, promoting recruitment of BRCA1 by p300 to
the p53-responsive promoter of p21 and inducing increased p21 expression

[10].

CARM1 is also recruited to the promoter of cyclin E1 (CCNE1) in an E2F-dependent
manner, and functions as a positive regulator of transcription [8]. Our analysis of growth
characteristics revealed that CARM1 null MEFs proliferated at a reduced rate when
compared to wildtype (Figure 3-7B) and had a smaller cell diameter and cell volume
(Figure 3-7D). Furthermore the expression of a large number of proteins known to
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regulate cell cycle was altered in the absence of CARM1 (Figure 3-8). To determine if
involvement of CARM1 in regulating the expression of cell cycle regulators has
functional impact, we subjected wildtype and knockout MEFs to the additional stress of a
cell replication inhibitor, hydroxyurea (HU), and found a substantial loss of cell viability
when CARM1 was absent. The suggestion that loss of CARM1 may sensitize cells to
replicative stress needs to be further evaluated in the future, and the model tested in
cancer cell lines known to have elevated CARM1. Alternately, and arguably of more
translational relevance, CARM1 expression could be assessed, along with the expression
of some of its downstream targets (ex. JAK2, p21) in breast tumor samples. Stratifying
tumors based on the presence or absence of CARM1 may allow for diagnostic and/or
prognostic inferences to be made with respect to the delineation of breast cancer
subtypes, and could ultimately suggest different therapeutic strategies. For example,
reduction of CARM1, or of its methyltransferase activity through the use of CARM1
inhibitors

[55,56], may prove to be a successful treatment approach when used in

combination with cell cycle inhibitors for cancers expressing high levels of CARM1.

4.8 Conclusions
The use of whole-genome approaches to characterize the role of the arginine
methyltransferase CARM1 in transcriptional regulation has advanced our understanding
of the myriad roles it plays. The work presented within this thesis describes the
recruitment of a functional p/CIP/CARM1 coregulatory complex to gene promoters in an
E2-dependent manner. Bioinformatic analysis suggests that direct binding via a classical
ERE is not the primary mechanism by which the complex is recruited, reinforcing
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accumulating evidence that transcription factor crosstalk commonly occurs in ERmediated transcription. I focus on the recruitment of a functional p/CIP/CARM1 complex
to the proximal promoter of Jak2, and demonstrate that regulation of Jak2 expression is
contingent on the presence of CARM1.
CARM1 recruitment was also characterized independent of p/CIP, and found to
bind predominantly at intergenic regions, consistent with the profiles of many other
transcriptional regulatory proteins. Enrichment of CARM1 binding events was also found
within the coding sequence of genes, suggesting an involvement in transcriptional
elongation; in support of this, interaction between CARM1 and the elongation-associated
Paf1c was confirmed. In addition, we identified the transcription factor PAX1 as a novel
mechanism through which CARM1 can interact with the genome. Overall, this study
suggested that direct genomic recruitment of CARM1 is not critical for its transcriptional
and functional effect(s) in an un-induced system; however, we observed an important
regulatory role for CARM1 in cellular growth and proliferation.
Moving forward, there are many more avenues to be pursued before we gain a
complete understanding of the many ways in which CARM1 contributes to the regulation
of gene expression, and affects diverse cellular processes. As technology advances, we
will be able to more fully characterize the coordinated action of transcriptional regulators
such as CARM1.
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Figure B-1 Co-occurrence of TF binding motifs in p/CIP/CARM1 target promoters
(A) Chart showing the overlap between ERE, Sp1, AP-1, FoxA1, C/EBPα, and Oct consensus
sites. The left column indicates the query motif(s), and the percentage of those promoters
containing overlapping motifs is listed left to right. Cells are color coded according to the
proportion overlap: red: >25% overlap, orange: 14-24.9% overlap, yellow <13.9% overlap. (B)
Venn diagrams showing overlap between p/CIP/CARM1 target promoters containing EREs and
those containing C/EBPα, Sp1, Oct, AP-1, or FoxA1 consensus sites.
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Figure B-2 Additional binding site analysis of p/CIP/CARM1 target promoter
sequences
Bar graphs showing the number of (A) ER-bound and (B) transcriptionally upregulated
p/CIP/CARM1 target promoters that contain ERE, Sp1, AP-1, FoxA1, C/EBP, and Oct binding
motifs.
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Table B-1 Genes directly targeted by the p/CIP/CARM1 complex.
Gene ID
TLR3
DBC1
LAP3
CLDN12
CRHR1
P181_E7
KRAS2
M6PR
PDCD8
CIRBP
DLGAP3
AES
BTN2A2
C10orf111
STARD6
GNG5
UNC13A

Accession Number
NM_003265
NM_014618
NM_015907
NM_012129
NM_004382
XM_372688
NM_033360
NM_002355
NM_004208
NM_001280
XM_035601
NM_198969
NM_006995
NM_153244
NM_139171
NM_005274
XM_038604

SLC4A5

NM_021196

PTER
TRAF3
C14orf29
ZNF800
ARMC3
LETM1
IL15RA
MAPK4
GTF2E2
SEC31L1
KRTHA4
IGSF4/CADM1
CASP6
KIAA1340
DRF1
OCA2
LOC343066
SLC26A1
FRMD1
AIP1
APRG1
CBR3
FCGRT
N4BP1
WDFY2
ZNF567
RAP140
PELO
OR51B4
SERPINB2

NM_030664
NM_003300
NM_181533
NM_176814
NM_173081
NM_012318
NM_002189
NM_002747
NM_002095
NM_016211
NM_021013
NM_014333
NM_001226
XM_044836
NM_025104
NM_000275
XM_291392
NM_022042
NM_024919
NM_012301
NM_178338
NM_001236
NM_004107
NM_153029
NM_052950
NM_152603
NM_015224
NM_015946
NM_033179
NM_002575

Description
Transmembrane receptor
Peptidase
Peptidase
Calcium-independent cell-cell adhesion
G-protein coupled receptor
Transporter
GTPase enzyme
Mannose-6-phosphate receptor (cation dependent)
Enzyme/cell death
Cold inducible RNA binding protein
Discs, large (Drosophila) homolog-associated protein 3
Amino-terminal enhancer of split/transcriptional regualtor
Butyrophilin, subfamily 2, member A2
Unknown
StAR-related lipid transfer (START) domain containing 6
Guanine nucleotide binding protein (G protein), gamma 5
Unc-13 homolog A (C. elegans)
Solute carrier family 4, sodium bicarbonate cotransporter, member
5
Phosphotriesterase related
TNF receptor-associated factor 3/apoptosis
Peptidase
Unkown
Armadillo repeat containing 3
Leucine zipper-EF-hand containing transmembrane protein 1
Interleukin 15 receptor, alpha
Mitogen-activated protein kinase 4
General transcription factor IIE, polypeptide 2, beta 34kDa
SEC31 homolog A (S. cerevisiae)/vesicle transport
Keratin 34
Cell adhesion molecule 1/tumour suppressor
Caspase 6, apoptosis-related cysteine peptidase
KLHDC5 kelch domain containing 5
DBF4 homolog B (S. cerevisiae)/cell cycle regulator
Oculocutaneous albinism II
Arylacetamide deacetylase-like 4
Solute carrier family 26 (sulfate transporter), member 1
FERM domain containing 1
MAGI2 membrane associated guanylate kinase
Unknown/tumour suppressor
Carbonyl reductase 3
Fc fragment of IgG, receptor, transporter, alpha
NEDD4 binding protein 1
WD repeat and FYVE domain containing 2
Transcription factor
Chromosome 3 open reading frame 63
Pelota homolog (Drosophila)
Olfactory receptor, family 51, subfamily B, member 4
Serpin peptidase inhibitor, clade B (ovalbumin), member 2
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DKFZP564I122
SEC31L1
TM4SF8
NJMU-R1
CTNND1
CDH7
FLJ14054
OR5T3
TPARL
CR2
ZIM3
VPS26A
MOCOS
POLR3F
MBD3
FLJ25467
A2LP
OR6C1
RAD9B
ECT2
PCSK5
GATM
TUBGCP6
KCTD16
CHRNA6
TGFB1
NEK4
CPT1C
OR7A10
FLJ23584
RPS4X
FLJ34969
MGC11386
ELAC1
STARD4
HRASLS
P188_B6
ENO2
P176_D4
PKP4
KIF24
OR2AP1
P155_A2
IFI6
DPH2L2
FUT7
SMARCAL1
CD9
LOC133609
SRISNF2L
POLR2E
NFKB1
C9orf95

XM_032397
NM_014933
NM_005724
NM_022344
NM_001331
NM_033646
NM_024563
XM_372393
NM_018475
NM_001877
NM_052882
NM_004896
NM_017947
NM_006466
NM_003926
NM_144719
NM_007245
XM_372459
NM_152442
NM_018098
NM_006200
NM_001482
NM_020461
XM_098368
NM_004198
NM_000660
NM_003157
NM_152359
XM_372712
NM_024588
NM_001007
NM_152678
NM_032933
NM_018696
NM_139164
NM_020386
XM_374513
NM_001975
XM_371127
NM_003628
NM_018278
XM_062467
XM_036408
NM_022873
NM_001384
NM_004479
NM_014140
NM_001769
XM_068430
NM_015106
NM_002695
NM_003998
NM_017881

Methylmalonic aciduria protein
SEC31 homolog A (S. cerevisiae)
Tetraspanin 3
Open reading frame 75
Catenin (cadherin-associated protein), delta 1
Cadherin 7, type 2
Open reading frame 23
Olfactory receptor, family 5, subfamily T, member 3
Transmembrane protein 165
Complement component (3d/Epstein Barr virus) receptor 2
Zinc finger, imprinted 3/transcription factor
Vacuolar protein sorting 26
Enzyme
Enzyme
Methyl-CpG binding domain protein 3
Coiled-coil domain containing 13
Homo sapiens ataxin 2-like (ATXN2L), transcript variant A
Homo sapiens olfactory receptor, family 6, subfamily C, member 1
RAD9 homolog B (S. cerevisiae)/DNA replication
Epithelial cell transforming sequence 2 oncogene
Proprotein convertase subtilisin/kexin type 5
Glycine amidinotransferase (L-arginine:glycine amidinotransferase)
Tubulin, gamma complex associated protein 6
Potassium channel tetramerisation domain containing 16
Cholinergic receptor, nicotinic, alpha 6
Growth factor
Enzyme
Carnitine palmitoyltransferase 1C
Olfactory receptor, family 7, subfamily A, member 10
Hypothetical protein
Ribosomal protein S4, X-linked
FAM116A family with sequence similarity 116, member A
C18orf45
ElaC homolog 1 (E. coli)/trna processing
StAR-related lipid transfer (START) domain containing 4
HRAS-like suppressor
Similar to KIAA1218 protein
Enolase 2 (gamma, neuronal)
Homo sapiens similar to putative protein
Plakophilin 4/cell adhesion
Homo sapiens kinesin family member 24 (KIF24)
Olfactory receptor, family 2, subfamily AP, member 1
Unknown orf (KIAA1228)
Interferon, alpha-inducible protein 6/apoptosis
DPH2 homolog (S. cerevisiae)
Fucosyltransferase 7 (alpha (1,3) fucosyltransferase)
SWI/SNF related, matrix associated, regulator of chromatin, a-like1
CD9 molecule/cell adhesion
Homo sapiens similar to 60S acidic ribosomal protein P1
RAD54-like 2 (S. cerevisiae)
Polymerase (RNA) II (DNA directed) polypeptide E, 25kDa
Nuclear factor of kappa light polypeptide gene enhancer
Orf
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GNL1
KRT20
TMEM16F
MGC15882
IVNS1ABP

NM_005275
NM_019010
XM_113743
NM_032884
NM_006469

DDX54

NM_024072

WBP11
OR10A5
SGK2
BMI1
LOC284275
K5B
MT1E
MT4
OTUB2
THEG
CARD9
ARHGAP8
ITPKB
LOC389253
C18orf26
POLR2F
LAMA1
P139_A6
SOD1
P163_B12
TSSC4
P181_D9
MAP3K7IP1
P2RY1
FLJ46299
TSHB
RDH10
KCNQ1
RPS15
LOC92691
KCTD3
HBD
LOC387635
PRKRIR
RAB6IP1
RFXAP
HDC
ZNF197
PCP4
LRFN4
ABAT
P186_C2
COL17A1
PTPRJ
PXMP4
JAK2

NM_016312
NM_178168
NM_170693
NM_005180
XM_211413
NM_173352
NM_175617
NM_032935
NM_023112
NM_199202
NM_022352
NM_181335
NM_002221
XM_374104
NM_173629
NM_021974
NM_005559
NM_152567
NM_000454
XM_114325
NM_005706
XM_372649
NM_006116
NM_002563
XM_093813
NM_000549
NM_172037
NM_000218
NM_001018
NM_138390
NM_016121
NM_000519
XM_370532
NM_004705
XM_290550
NM_000538
NM_002112
NM_006991
NM_006198
NM_024036
NM_000663
XM_373988
NM_000494
NM_002843
NM_007238
NM_004972

Guanine nucleotide binding protein-like 1
Keratin 20/apoptosis
Transmembrane protein 16F
C1orf94
Influenza virus NS1A binding protein
DEAD (Asp-Glu-Ala-Asp) box polypeptide 54/tranascriptional
regulator
WW domain binding protein 11
OR10A5 olfactory receptor, family 10, subfamily A, member 5
Serum/glucocorticoid regulated kinase 2
BMI1 polycomb ring finger oncogene
Hypothetical protein
Keratin 5b
Metallothionein 1E
Metallothionein 4
OTU domain, ubiquitin aldehyde binding 2
Theg homolog (mouse)
P111_E11
Rho GTPase activating protein 8
Inositol 1,4,5-trisphosphate 3-kinase B
Hypothetical protein
Orf
Polymerase (RNA) II (DNA directed) polypeptide F
Laminin, alpha 1/cell adhesion protein
Arabidopsis thaliana chromosome 1
Superoxide dismutase 1, soluble
Homo sapiens ubiquitin specific protease 19 (USP19)
Tumor suppressing subtransferable candidate 4
Hypothetical protein CBG22662
Mitogen-activated protein kinase kinase kinase 7 interacting protein
Purinergic receptor P2Y, G-protein coupled, 1
Homo sapiens similar to hypothetical protein (LOC166348)
Thyroid stimulating hormone, beta
Retinol dehydrogenase 10 (all-trans)
Potassium voltage-gated channel, KQT-like subfamily, member 1
Ribosomal protein S15/translation
Unknown
Potassium channel tetramerisation domain containing 3
Hemoglobin, beta /// hemoglobin, delta
Similar to ubiquitin-conjugating enzyme E2 variant 1
Protein-kinase, interferon-inducible RNA dependent inhibitor,
RAB6 interacting protein 1
Regulatory factor X-associated protein
Histidine decarboxylase
Zinc finger protein 197/transcription factor
Purkinje cell protein 4
Leucine rich repeat and fibronectin type III domain containing 4
4-aminobutyrate aminotransferase
Homo sapiens similar to protein 40kD (LOC388290), mRNA.
Collagen, type XVII, alpha 1
Protein tyrosine phosphatase, receptor type, J
Peroxisomal membrane protein 4, 24kDa
Janus kinase 2 (a protein tyrosine kinase)
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PRSS15
C6orf146
LOC389439
TRO
GPR132
HARS
MDS009
VN1R5
CCNA2
DMP1
PCDHGC5
POLG
ZBED2
HSD17B12

NM_004793
NM_173563
XM_374187
NM_177557
NM_013345
NM_002109
NM_020234
NM_173858
NM_001237
NM_004407
NM_018929
NM_002693
NM_024508
NM_016142

lon peptidase 1, serine protease
Orf
Homo sapiens LOC389439 (LOC389439), mRNA
Trophinin/cell adhesion
G protein-coupled receptor 132
Histidyl-tRNA synthetase
DTWD1 DTW domain containing 1
Vomeronasal 1 receptor 5
Cyclin A2/cell cycle
Dentin matrix acidic phosphoprotein
Protocadherin gamma subfamily C, 5
Polymerase (DNA directed), gamma
Zinc finger, BED-type containing 2
Hydroxysteroid (17-beta) dehydrogenase 12

LOC126298

XM_065026

Homo sapiens immunity-related GTPase family, Q (IRGQ), mRNA

CSNK1A1L
CYC1
AKAP13
LMOD1
RBM29
P097_A6
LOC338731
LOC131873
MAP6
SS18L1
PIAS2
DPYS
RPS27L
FXR1
NAGA
IDH3G
PROS1
DYRK1A

NM_145203
NM_001916
NM_006738
NM_012134
NM_032213
NM_017597
XM_294688
XM_067585
XM_166256
NM_015558
NM_004671
NM_001385
NM_015920
NM_005087
NM_000262
NM_004135
NM_000313
NM_101395

Casein kinase 1, alpha 1-like
Cytochrome c-1
A kinase (PRKA) anchor protein 13
Leiomodin 1 (smooth muscle)
RNA binding motif and ELMO/CED-12 domain 1
Homo sapiens hypothetical protein
Hypthetical protein
Hypothetical protein
Microtubule-associated protein 6
Synovial sarcoma translocation gene on chromosome 18-like 1
Protein inhibitor of activated STAT, 2
Dihydropyrimidinase
Ribosomal protein S27-like
Fragile X mental retardation, autosomal homolog 1
N-acetylgalactosaminidase, alphaIsocitrate dehydrogenase 3 (NAD+) gamma
Protein S (alpha)
Dual-specificity tyrosine-(Y)-phosphorylation regulated kinase 1A
Homo sapiens enhancer of mRNA decapping 3 homolog (S.
EDC3
NM_025083
cerevisiae)
TNFRSF19L
NM_152222
RELT tumor necrosis factor receptor
SLC39A10
XM_047707
Solute carrier family 39 (zinc transporter), member 10
SAMD3
NM_152552
Sterile alpha motif domain containing 3
FLRT2
NM_013231
Fibronectin leucine rich transmembrane protein 2/cell adhesion
MGC14156
NM_032906
PIGY phosphatidylinositol glycan anchor biosynthesis, class Y
BPI
NM_001725
NEDD4 binding protein 1
LOC341511
XM_292109
Homo sapiens similar to 60S ribosomal protein L23a
C6orf188
NM_153711
Hypothetical protein
MXD3
NM_031300
MAX dimerization protein 3
LGR6
NM_021636
Leucine-rich repeat-containing G protein-coupled receptor 6
PCNA
NM_002592
Proliferating cell nuclear antigen
P162_C9
XM_096669
Homo sapiens hypothetical LOC144705
GAD1
NM_013445
Glutamate decarboxylase 1 (brain, 67kDa)
FLJ11331
NM_018392
C4orf21
CMYA4
NM_173167
Unc-45 homolog B
P181_E10
XM_372694
imilar to RIKEN cDNA C230094B15
P188_D7
XM_374566
Homo sapiens similar to T-cell receptor beta
a
Genes show 2-fold enrichment or greater and p value <0.05.
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Table B-2 Enriched motifs within p/CIP/CARM1 target promoters.
Motif

p-value

Yes

No

Enrichment (Yes/No)

0.000

0.5028

0.0000

inf

V$ZF5_B

3.99E-41

0.2712

0.0000

inf

V$ETF_Q6

2.77E-40

0.2655

0.0000

inf

V$SP1_Q2_01

1.08E-24

0.1977

0.0089

22.1458

V$PAX4_01

1.31E-22

0.1469

0.0000

inf

V$POU3F2_02

1.96E-22

0.1695

0.0054

31.6394

V$POU3F2_01

4.34E-22

0.2203

0.0250

8.8136

V$OG2_01

1.44E-21

0.1751

0.0089

19.6149

V$CDXA_02

3.52E-21

0.1921

0.0161

11.9526

V$PAX4_02

1.91E-18

0.1412

0.0054

26.3661

V$CETS1P54_03

2.12E-18

0.1186

0.0000

inf

V$FOXJ2_02

8.53E-17

0.1525

0.0107

14.2376

V$PAX4_03

1.47E-17

0.1130

0.0000

inf

V$PLF_02

4.25E-16

0.1299

0.0071

18.1918

V$SREBP1_01

4.49E-16

0.1243

0.0054

23.2022

V$KROX_Q6

4.49E-16

0.1243

0.0054

23.2022

V$TST_01

4.63E-16

0.1525

0.0161

9.4918

V$PAX5_02

7.09E-16

0.1017

0.0000

inf

V$WT1_Q6

7.09E-16

0.1017

0.0000

inf

V$HOX13_01

1.25E-14

0.1412

0.0161

8.7887

V$CART1_01

8.66E-14

0.1130

0.0071

15.8188

V$OCT4_02

1.01E-13

0.1073

0.0054

20.0383

V$NKX25_02

1.69E-13

0.1243

0.0125

9.9435

V$AP4_01

1.69E-13

0.1243

0.0125

9.9435

V$AP2_Q6

2.58E-13

0.1186

0.0107

11.0737

V$IPF1_Q4

5.14E-13

0.1356

0.0196

6.9029

V$GABP_B

6.07E-13

0.1017

0.0054

18.9836

V$SRY_02

6.07E-13

0.1017

0.0054

18.9836

V$CEBPGAMMA_Q6

8.91E-13

0.1186

0.0125

9.4915

V$CHOP_01

7.48E-12

0.1073

0.0107

10.0191

V$CDPCR3_01

7.48E-12

0.1073

0.0107

10.0191

V$AP2_Q6_01

1.41E-11

0.1130

0.0143

7.9094

V$NCX_01

1.45E-11

0.1864

0.0607

3.0708

V$TEL2_Q6

1.22E-10

0.1017

0.0125

8.1356

V$XVENT1_01

1.28E-10

0.1186

0.0214

5.5366

V$MAZ_Q6

1.55E-10

0.1356

0.0321

4.2184

V$OCT1_02

1.88E-10

0.1073

0.0161

6.6794

V$PAX4_04

8.90E-10

0.1017

0.0161

6.3279

V$KID3_01
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V$BRCA_01

1.11E-09

0.1073

0.0196

5.4648

V$FAC1_01

2.42E-09

0.1243

0.0321

3.8669

V$OCT1_03

4.90E-09

0.1017

0.0196

5.1772

V$HNF3ALPHA_Q6

4.90E-09

0.1017

0.0196

5.1772

V$RFX1_02

4.97E-09

0.1186

0.0304

3.9083

V$PAX3_B

5.26E-09

0.1130

0.0268

4.2184

V$TBX5_01

5.26E-09

0.1073

0.0232

4.6241

V$HMGIY_Q6

1.06E-08

0.1017

0.0214

4.7457

V$CP2_02

1.06E-08

0.1017

0.0214

4.7457

V$VDR_Q3

1.06E-08

0.1017

0.0214

4.7457

V$PAX6_01

1.63E-08

0.1356

0.0464

2.9204

V$HAND1E47_01

3.49E-08

0.1638

0.0732

2.2379

V$CEBPDELTA_Q6

8.21E-08

0.1017

0.0268

3.7966

V$STAT1_01

8.21E-08

0.1017

0.0268

3.7966

V$CKROX_Q2

1.19E-07

0.1412

0.0589

2.3968

V$GATA4_Q3

1.51E-07

0.1017

0.0286

3.5594

V$PAX8_01

4.28E-07

0.2429

0.1696

1.4321

V$GRE_C

4.35E-07

0.1243

0.0500

2.4859

V$AP2ALPHA_01

7.82E-07

0.1017

0.0339

2.9973

V$CEBP_Q3

9.97E-07

0.1073

0.0393

2.7324

V$VMYB_02

1.28E-06

0.1017

0.0357

2.8475

V$CREB_Q4_01

1.57E-06

0.1073

0.0411

2.6136

V$TAXCREB_02

2.06E-06

0.1017

0.0375

2.7119

V$PAX6_Q2

3.07E-06

0.1243

0.0589

2.1092

V$AP1_Q2_01

5.01E-06

0.1017

0.0411

2.4761

V$RFX_Q6

5.56E-06

0.1073

0.0464

2.3120

V$BCL6_Q3

5.92E-06

0.1130

0.0518

2.1819

V$LRF_Q2

6.11E-06

0.1186

0.0571

2.0763

V$PPARG_02

7.58E-06

0.1017

0.0429

2.3729

V$PAX5_01

8.55E-06

0.1243

0.0643

1.9335

V$PAX_Q6

1.12E-05

0.1525

0.0946

1.6118

V$USF_Q6_01

1.13E-05

0.1017

0.0446

2.2780

V$LEF1TCF1_Q4

1.18E-05

0.1243

0.0661

1.8812

V$MAF_Q6_01

0.1017

0.0464

2.1903

V$PAX2_02

1.65E-05
1.70E-05

0.1073

0.0518

2.0729

V$MYB_Q3

3.36E-05

0.1073

0.0554

1.9391

V$TTF1_Q6

4.63E-05

0.1073

0.0571

1.8785

V$PPARA_01

4.65E-05

0.1299

0.0804

1.6171

V$ER_Q6

4.75E-05

0.1017

0.0518

1.9638

V$CACD_01

6.31E-05

0.1073

0.0589

1.8216
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V$NKX25_Q5

6.58E-05

0.1017

0.0536

1.8983

V$TAL1BETAE47_01

6.58E-05

0.1017

0.0536

1.8983

V$ZIC2_01

9.01E-05

0.1017

0.0554

1.8371

V$SPZ1_01

1.22E-04

0.1017

0.0571

1.7797

V$CDP_02

1.63E-04

0.1017

0.0589

1.7257

V$STAT_Q6

1.63E-04

0.1017

0.0589

1.7257

* Cutoff conditions p < 0.001, Yes/No > 1.2

Table B-3 Primer List.
ChIP Validations:
Gene Target

5’

3’

pS2

GGCCATCTCTCACTATGAATCACTTCTGC

GGCAGGCTCTGTTTGCTTAAAGAGCG

CyclinA2

GCTAACTAGACGTCCCAGAGC

GGGGAGAGGTAGGATTTAGG

NFkB1

GCCTGGTACACTATAGCAGTC

ATCGCCCTCTGAACTTCAAC

WBP11

GGGCGAAGGCTAGAGT_AAGT

GATTGCTTATATGGGCGGTG

DYRK1A

CCTCTTCTGCTGATTATCAGT

CTGAGACATTTCTCACAACC

IL15RA

GTCTGCTCTCCGATGACTTTG

CAGGACCTTACCCACGCAAG

MAPK4

GAACTCTGCACCCTGGTTTC

TTGCACTTGGGTTCCTTTTC

TGFB1

GGTCGGGAGAAGAGGAAAAA

CTGAGGGACGCCGTGTAG

NEK4

CTTTGGCTGGAACAAATGGT

CCCTAAAAACTCGCCTGCTA

KRAS2

ATTTCCCCATGACACAATCC

ACCCTGTAGCACACCCTCAC

Assessing Chromatin Modifications on JAK2:
Assay

5’

3’

ChIP

AAGGTGGCTGATGGGAGTC

CTTTCGGCTTTTCCTTCCAC

qChIP

GGTGGCTGATGGGAGTCAGG

GCTTTCGGCTTTTCCTTCCACC

Table B-4 Antibody List.
Antibody Name
p/CIP

Source

Catalogue #

* In House

CARM1

CARM1 Antibody

Cedarlane

A300-421A

ER

ERα (HC-20)

Santa Cruz Biotechnology

sc-543

JAK2

JAK2 (C-14)

Santa Cruz Biotechnology

sc-34479

Upstate

07-214

AbCam

ab1012

Millipore

07-585

Upstate

06-599

H3R17me2
H3K4me3
H3R2me2
H3Ac(K9, K14)

Anti-dimethyl-Histone H3 (Arg17)
(rabbit immunoaffinity purified IgG)
Mouse monoclonal to Histone H3
(tri methyl K4)
Anti-dimethyl-Histone H3 (Arg2)
(rabbit antiserum)
Anti-acetyl-Histone H3
(rabbit polyclonal IgG)

STAT3

Stat3 (79D7) (rabbit mAb)

Cell Signaling Technology

#4904

P-STAT3

Phospho-Stat3 (Tyr705)

Cell Signaling Technology

#9131
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Appendix C: Supplementary Information for Chapter 3: Whole
Genome analysis of CARM1 in wildtype and CARM1-knockout
Mouse Embryonic Fibroblasts.

Figure C-1 Additional characterization of CARM1 genome-wide binding
(A) ChIP analysis validating CARM1 recruitment to indicated genomic regions, identified by
ChIP-Seq. (B) CARM1 binding frequencies; analysis of the number of genes with 1-2, 3-5, or 6+
CARM1 binding events within 50kb of TSS. Correlation of CARM1 (C) binding sites or (D)
MW-enriched regions with chromosome length. (E) Bar chart depicting the prevalence of number
of multiple CARM1 binding events within 50kb of the TSS on each chromosome.
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Figure C-2 Chromosomal view depicting co-occurrence of CARM1 enriched regions
and PAX1 motifs

αPAX1
αVinculin

Figure C-3 siRNA-mediated depletion of PAX1 in wildtype MEFs

160

Primers used for ChIP Validations:
Apbb1ip F: AACGGGGAGTGGGAAAGAT
Apbb1ip R: AAGCGGGTGGTAAACTCCAT
Ctnnd2 F: GCCTTGCCCTAAGAGTAGCTT
Ctnnd2 R: ACGTGTGGCCCTAGAGCTT
Gm7120 F: GGAGCTCCTCTGCTGGAATA
Gm7120 R: ACAGTCACACAGCCACACC
Raet1d F: GGAGCAAGCGAAAATGATTG
Raet1d R: CCTGAACAGGTATCAATGCAAA

Primers used for Pax-1 ChIPs:
Chr 1- Col9a1 F: AACAATTCATGCGCATTCTG
Chr 1 - Col9a1 R: GGCAGAACTCGGACAGTCAT
Chr4 - Mllt3 F: TCAAGCTTGTTCAGATGTGAAATTA
Chr4 - Mllt3 R: CCCACTTTGCCAGTTTAGGA
Chr5 - Mag2 F: GGATAGTGATTCCCCCAGAAG
Chr5 - Mag2 R: ATGTCCATCTTGCCAAAAGC
Chr9 - Mir101c F: GACTGTGCAATTGGGGAGTAA
Chr9 - Mir101c R: CTGCCCAACCTAAAGTCCTG
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